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ABSTRACT 
 
 The comorbidity between female sexual dysfunction (FSD) and major depressive 
disorder (MDD) is well documented; however, the mechanism(s) underlying the 
relationship between these disorders has not been defined. The literature has associated 
the adrenal hormones cortisol and dehydroepiandrosterone (DHEA) with FSD and MDD, 
suggesting a biological mechanism that may elucidate the comorbidity between these 
disorders. Based on evidence pointing to a high cortisol/DHEA ratio (C/D Ratio) in MDD 
and low DHEA in FSD, this study investigated if the potential association between a high 
C/D Ratio and FSD would be greater for women with a history of MDD when compared 
to women without a history of MDD. Two groups of women (MDD history group; 
control group), each with a range of sexual function, collected saliva samples, completed 
questionnaires, and participated in a clinical interview and a psychophysiological 
assessment. 
 
Results did not support the hypothesis that the relationship between the C/D Ratio and 
sexual function would be greater for women with a history of MDD. Relevant to the 
effects of hormones on sexual function, a higher C/D Ratio was associated with lower 
frequency of sexual activity and lower sexual assertiveness. Results also showed DHEA 
positively associated with overall frequency of sexual activity, while cortisol was 
associated with lower subjective assessment of sexual desire/arousal prior to erotic 
stimuli. Lastly, secondary analyses revealed a positive association between DHEA and 
frequency of sexual activity, which was mediated by women's sexual desire.  
 
These results suggest that the effects of the C/D Ratio on FSD are not associated with a 
history of MDD. Results also point to contrasting roles for C/D Ratio and DHEA in FSD. 
In particular, a high C/D Ratio may have inhibitory effects on frequency of sexual 
activity and sexual assertiveness, while high DHEA may have facilitatory effects on 
sexual activity frequency through heightened sexual desire. Lastly, high cortisol may 
predispose women to have a negative assessment of sexual stimuli. These findings 
contribute to a further understanding of the roles of the C/D Ratio, DHEA, and cortisol in 
female sexuality and offer support for future studies investigating the role of these 
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1 CHAPTER 1: INTRODUCTION 
 
             It is well documented that women with depression frequently report comorbid 
sexual dysfunction (Angst, 1998; Bonierbale & Tignol, 2003; Clayton, McGarvey, 
Clavet, & Piazza, 1997; Cyranowski, Frank, Cherry, Houck, & Kupfer, 2004; Fabre & 
Smith, 2012; Lai, 2011), and that similarly, women with sexual dysfunction often report 
depression (Dunn, Croft, & Hackett, 1999; Hartmann, Philippsohn, Heiser, & Rüffer-
Hesse, 2004; Hayes, Dennerstein, Bennett, Sidat, et al., 2008; Shifren, Monz, Russo, 
Segreti, & Johannes, 2008). Indeed, evidence suggests that 50% of women with major 
depressive disorder (MDD) experience a decrease in sexual drive and sexual arousal 
(Kennedy, Dickens, Eisfeld, & Bagby, 1999); nonetheless, the mechanisms underlying 
the relationship between depression and female sexual dysfunction (FSD) have not been 
defined (Bancroft & Graham, 2011; Basson, Brotto, Petkau, & Labrie, 2010). Moreover, 
since the majority of research on female sexuality is conducted with women without 
mood disorders, we know little about treating FSD in women presenting with 
comorbidity (Clayton, 2010; Michael & O'Keane, 2000). The present study will provide 
the first empirical investigation of a potential biological mechanism that may elucidate 
the relationship between MDD and FSD, specifically, the ratio between the classic stress 
hormone cortisol and the hormone dehydroepiandrosterone (DHEA) and its sulfate ester, 
dehydroepiandrosterone sulfate (DHEA-S), which will jointly be referred to as DHEA(S) 




 Although the steroid hormone cortisol has long been implicated in the 
hypothalamic-pituitary-adrenal (HPA) axis response to stress, recent evidence suggests 
that other adrenal steroids including DHEA(S) play a role in mediating the stress 
response (Gallagher & Ritsner, 2009; Goodyer, 2007; Hechter, Grossman, & Chatterton, 
1997). In particular, research indicating that DHEA(S) antagonizes the negative actions 
of cortisol in the brain (Kaminska, Harris, Gijsbers, & Dubrovsky, 2000), suggests that 
the cortisol/DHEA(S) ratio may more accurately assess HPA axis function than cortisol 
alone, with lower ratios associated with more positive function (Gallagher & Ritsner, 
2009; Goodyer, Park, Netherton, & Herbert, 2001; Markopoulou et al., 2009; Yen & 
Laughlin, 1998). Indeed, results from across studies indicate that a high basal cortisol/ 
DHEA(S) ratio may be a “state marker” of depression (Goodyer, Herbert, & Tamplin, 
2003; Markopoulou et al., 2009; Michael, Jenaway, Paykel, & Herbert, 2000; H. Young, 
Gallagher, & Porter, 2002); however, the relationship between the cortisol/DHEA(S)  
ratio and FSD is unknown. Although little is known about basal cortisol levels in women 
with FSD (Basson et al., 2010), studies associating low concentrations of  DHEA(S) in 
women with lower sexual function (Basson et al., 2010; S. Davis, Davison, Donath, & 
Bell, 2005; Guay et al., 2004; Turna et al., 2005), suggest that FSD may also be 
associated with a high cortisol/DHEA(S) ratio (Basson et al., 2010; Hamilton & Meston, 
2010). It is feasible that a high cortisol/DHEA(S) ratio observed in MDD may exert 
various direct and indirect effects on sexual function, suggesting a common biological 




However, to date, no study has directly investigated the relationship between a high 
cortisol/DHEA(S) ratio and FSD.  
 
1.1 Depression and Female Sexual Dysfunction 
1.1.1 Depression: Prevalence 
 Findings from the World Health Organization indicate that major depression is 
the leading worldwide cause of disease-related disability in women (Murray & Lopez, 
1996). As defined by the Diagnostic and Statistical Manual of Mental Disorders: Fifth 
Edition (DSM-5), major depressive disorder (MDD) is characterized by depressed or sad 
mood and/or reduced interest or pleasure, accompanied by several symptoms, including 
disturbances in sleep and appetite, psychomotor agitation or retardation, fatigue or loss of 
energy, feelings of worthlessness or guilt, difficulty concentrating, and/or suicidal 
ideation/attempt (APA, 2013). In addition, changes in mood must occur for a minimum 
of two weeks and be accompanied by significant distress or impairment in life 
functioning. The lifetime prevalence estimates for depression in women vary from 10% 
to 25%, with an average prevalence rate of approximately 20% (Desai & Jann, 2000). 
Moreover, women are nearly twice as likely as men to report a lifetime history of a major 
depressive episode (MDE) (Kessler, 2003) and have nearly twice the genetic risk for 
developing MDD (Kendler, Gatz, Gardner, & Pedersen, 2006). The high prevalence of 
depression among women is evident from puberty, with brief rise during perimenopause 
(Freeman et al., 2004; Schmidt et al., 2005), and a decline after menopause (Kessler, 




1.1.2 Depression: Pathophysiology 
 There are currently many biological theories to explain the pathophysiology of 
MDD. The two current predominate theories of depression (Belmaker & Agam, 2008) are 
the stress/HPA axis hypothesis of depression, which proposes a dysregulation in the 
stress response system, characterized by hyperactivity in the cortisol response to stress 
(Belmaker & Agam, 2008; Carroll et al., 2007; Gold & Chrousos, 2002), and the 
monoamine-deficiency hypothesis, which proposes a deficiency in serotonin or 
norepinephrine neurotransmission in the brain (Belmaker & Agam, 2008; Meyer et al., 
2006). Other biological theories hypothesize that altered glutamatergic 
neurotransmission, reduced GABAergic neurotransmission, and deficient neurosteroid 
synthesis may play a role in depression (Belmaker & Agam, 2008). A theory that may 
explain the greater prevalence of MDD in women is suggested by evidence indicating 
that women may have a more intense HPA axis response to stress than men due to 
cyclical fluctuations in hormones (Ferin, 2006), which may potentially increase the risk 
for depression (E. Young & Korszun, 2010).  Of particular interest to the current study is 
the stress/HPA axis hypothesis of depression, given its potential to be a common 
mechanism linking depression and FSD.  
 
1.1.3 Female Sexual Dysfunction: Prevalence 
 Similar to depression, FSD is highly prevalent and encompasses a range of sexual 
function difficulties, including low sexual desire and low sexual arousal (Basson, 2006), 




disorder (HSDD) as defined by the DSM-IV-TR is the deficiency (or absence) of sexual 
fantasies/thoughts, and/or desire for sexual activity, while sexual arousal disorder (SAD) 
refers to the inability to achieve, or maintain an adequate genital lubrication-swelling 
response (APA, 2000). Recently, the DSM-V combined these two disorders into the 
female disorder of sexual interest/arousal, which, in addition to the criteria for HSDD, 
includes absent/decreased activity in: initiation of sexual activity/responsiveness, 
excitement/pleasure, response to sexual cues, and genital/non-genital sensations (APA, 
2013). For diagnosis a women must meet three of the six total criteria. 
 Although not defined by the DSM-IV-TR, problems with sexual arousal may also 
refer to the lack of a subjective sense of sexual arousal (Clayton, 2010).  Moreover, 
studies show that women often have difficulty distinguishing sexual desire from 
subjective sexual arousal, which may explain the high rate of comorbidity between 
HSDD and SAD (Brotto, Bitzer, Laan, Leiblum, & Luria, 2010). Indeed, the distinction 
between sexual desire and subjective sexual arousal has been challenged by some 
researchers who posit that sexual desire may be a cognitive component of the sexual 
arousal domain (Prause, Janssen, & Hetrick, 2008).  
 Current diagnostic guidelines stipulate that to qualify as a disorder, FSD must be 
accompanied by sexually related personal distress (APA, 2000; Basson et al., 2000). 
Results from a well-publicized, population-based study, suggests that approximately 43% 
of U.S. women experience sexual problems (Laumann, Paik, & Rosen, 1999). However, 
studies that look at the prevalence of FSD with distress assessed as a cofactor report 




Bennett, & Fairley, 2008; Shifren et al., 2008), indicating that approximately 12% -15% 
of women are distressed about low sexual function (desire, arousal, and/or orgasm) 
(Hayes et al., 2007; Shifren et al., 2008). Findings from a large, population-based U.S. 
study indicate that the prevalence of female sexual problems associated with distress 
peaks between the ages 45-64 (14.8%) (Shifren et al., 2008), while another large study 
reports rates for low desire associated with distress peaking between the ages 30-39 
(Hayes et al., 2007).  
 
1.1.4 Female Sexual Dysfunction: Neurobiology.  
 The neurobiology of female sexual function is linked to a complex interplay of 
hormones and neurotransmitters, which affect sexual function both at the peripheral 
(genital arousal) and central (desire and subjective arousal) levels (Clayton, 2003; 
Goldstein, Traish, Kim, & Munarriz, 2004). Although it is generally believed that 
difficulties in female sexual desire are associated with low levels of testosterone, while 
difficulties in genital receptivity and lubrication are associated with low levels of 
estrogens (Nappi & Polatti, 2009), results from across studies paint a more complex 
picture, suggesting that multiple hormones and neurotransmitters must act in concert for 
satisfactory sexual functioning to occur (Clayton, 2007). For example, although reduced 
sexual desire is commonly associated with reduced levels of testosterone (Kingsberg et 
al., 2007), large empirical studies do not support the association between sexual desire 




 At the peripheral level, androgens, estrogens, and progesterone released by the 
ovaries and the adrenal glands are involved in regulating genital structure and sexual 
function (Bancroft, 2009). In particular, evidence suggests that the sex steroids modulate 
genital blood flow and maintain genital tissues involved in vaginal sensation and 
lubrication, emphasizing their potential role in physiological sexual arousal (Munarriz, 
Kim, Goldstein, & Traish, 2002; Traish, Goldstein, Munarriz, & Guay, 2006). The 
synthesis of ovarian androgens and estrogens are regulated by the hormones of the 
reproductive hypothalamus-pituitary-gonadal (HPG) axis (Ferin, 2006). Androgens and 
estrogens are also synthesized in peripheral target tissues from the steroid hormone 
DHEA(S) from adrenal origin (Labrie, 2001). Recent evidence suggests that DHEA(S)  
also plays a role in regulating clitoral vasocongestion and genital arousal, through its 
effects on the signaling molecule nitric oxide (Liu & Dillon, 2004). 
 Numerous studies suggest that sexual arousal, motivation, and receptive behavior 
at the central level are regulated by a complex interaction of steroids arriving from the 
periphery via circulation (Genazzani, Pluchino, Freschi, Ninni, & Luisi, 2007), by 
neurosteroids synthesized de novo in the brain (King, 2008), and by neurotransmitters 
including dopamine, norepinephrine and serotonin (Pfaus, 2009). Evidence suggests that 
the sex steroid hormones (androgens, estrogens, and progestogens) play a role in 
activating the mechanisms of central desire and arousal in the hypothalamic-limbic area 
of the brain by binding to hormone receptors that influence the release of 




sexual stimuli (Hull et al., 1999; Pfaus, 2009). Neurosteroids also play a strong role in 
regulating the neurotransmitters implicated in stress and depression (King, 2008). 
 
1.1.5 Comorbidity: Depression and Female Sexual Dysfunction 
 It is commonly acknowledged that depression and FSD are often comorbid in 
women (Baldwin, 2001; Bonierbale & Tignol, 2003; Casper et al., 1985). Studies indicate 
that women with depression are more likely to experience decreased sexual desire and/or 
interest (Clayton et al., 1997; Cyranowski, Frank, et al., 2004; Kennedy et al., 1999; Lai, 
2011), and decreased sexual arousal (Cyranowski, Frank, et al., 2004; Kennedy et al., 
1999; Lai, 2011). Similarly, results from large cross-sectional, population-based studies 
suggest that women reporting low sexual function, including low sexual desire, low 
sexual arousal, and sexually-related distress, are two times more likely to be depressed 
than women without sexual dysfunction (Hayes, Dennerstein, Bennett, Sidat, et al., 2008; 
Shifren et al., 2008). Supporting these findings are reports indicating that mental well-
being is one of the best predictors of quality of sexual life (Cawood & Bancroft, 1996), 
and that mental health problems are significant predictors of sexual interest and desire 
(Hartmann et al., 2004). Nonetheless, not all studies demonstrate consistent effects of 
mood on sexuality. Depression in college-aged women has been associated with reported 
greater frequency of masturbation (Frohlich & Meston, 2002), and depression in female 
adolescents is linked with greater sexual experience (Kowaleski-Jones & Mott, 1998).  
 Studies assessing the effects of mood modification on sexual responses report 




that subjects reported significantly less subjective sexual arousal and negative affect in 
the sad mood condition than in the happy mood condition, but observed no effects of 
mood induction on genital arousal responses (Ter Kuile, Both, & Van Uden, 2010). A 
second study investigating the effects of experimentally adopted positive and negative 
sexual schemas on sexual function, revealed that women in the positive schema condition 
demonstrated significantly greater subjective sexual arousal and vaginal response than 
women in the negative schema condition (Kuffel & Heiman, 2006).  
 However, for women with MDD, the literature is not clear if sexual difficulties 
are a consequence of MDD or reflect an association with one or more biological 
mechanisms implicated in MDD (Williams & Reynolds, 2006). Indeed, since not all 
women with depression experience FSD, and some even report increased sexual activity 
(Frohlich & Meston, 2002), the comorbidity between MDD and FSD is more relevant for 
some women than for others. A potential distinction between MDD and FSD is supported 
by evidence indicating that while selective serotonin reuptake inhibitors (SSRIs) are often 
effective in treating MDD, SSRI’s increase the risk for FSD (Clayton et al., 2002). 
 
1.2 The HPA Axis, Cortisol, and DHEA(S) 
1.2.1 Potential Effects of a High Cortisol/DHEA(S) Ratio on Sexual Function 
 Theoretical (Bancroft & Graham, 2011; Basson et al., 2010; Goldstein et al., 
2004; Michael & O'Keane, 2000) and empirical (Basson et al., 2010; S. Davis et al., 
2005; Guay et al., 2004) evidence suggests that the relationship between MDD and FSD 




DHEA(S). In particular, evidence that the chronic hyperactivation of the stress response 
in MDD may result not only in cortisol hypersecretion, but in the reduced secretion of 
adrenal DHEA(S) (Goodyer, 2007), suggests numerous pathways in which a high 
cortisol/DHEA(S) ratio may potentially impact sexual function through direct effects on 
sexual functioning or through indirect effects on mood. While the current research goal is 
not to determine the specific mechanisms that potentially link MDD to FSD, an 
elucidation of these pathways provides a theoretical basis for the present study. 
Specifically, at the peripheral level, hypersecretion of cortisol may have a negative 
impact on the HPG axis (Chrousos, Torpy, & Gold, 1998), resulting in reduced ovarian 
estrogen and testosterone release, with a potential negative impact on peripheral sexual 
function (Goldstein et al., 2004). Moreover, reduced adrenal DHEA(S) secretion may 
result in decreased synthesis of sex steroids in peripheral tissues, thus impacting genital 
sexual arousal responses (Goldstein et al., 2004; Traish, Kang, Saad, & Guay, 2011). 
Reduced adrenal DHEA(S) may also have a direct impact on peripheral sexual arousal 
responses by decreasing nitric oxide facilitated relaxation of the clitoral smooth muscles 
(Lee et al., 2009; Liu & Dillon, 2004). At the central level, lowered concentrations of sex 
steroids arriving from the periphery, as a result of reduced adrenal DHEA(S) secretion, 
may lead to reduced central neurosteroid levels, thus impacting the regulation of the 
central neurotransmitters involved in sexual desire, motivation, and arousal (Chrousos et 
al., 1998; Kalantaridou, Makrigiannakis, Zoumakis, & Chrousos, 2004; Steiner, Dunn, & 
Born, 2003). Moreover, the effects of excessive glucocorticoid activity on the amygdala 




which may, in turn, have secondary effects on sexual function. Reduced adrenal 
DHEA(S) may also impact mood at the central level through lowered effects on the 5-
HT1A receptor, the γ-aminobutyric acid type A (GABAA) receptor, the N-methyl-D-
aspartate (NMDA) receptor, and the sigma subtype 1 (σ1) receptor (Belmaker & Agam, 
2008). 
 
1.2.2 The HPA Axis: Overview 
 The HPA axis functions as a central control and regulation system, linking the 
central nervous system with the endocrine system. Stress occurs when the body is 
exposed to a stressor (either physiological or psychological) that disrupts homeostatic 
balance (Sapolsky, 2004). The stress response is the attempt of body to deal with stressor 
and reestablish homeostasis. Along with the sympathetic nervous system, the HPA axis 
regulates the maintenance of homeostasis in the body by initiating a cascade of hormones 
in response to stress (Ferin, 2006). In particular, perceived stress elicits the secretion of 
corticotropin releasing hormone (CRH) from the hypothalamus, which in turn stimulates 
the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, resulting in 
the release of the glucocorticoid hormone cortisol from the zona fasciculata in the adrenal 
cortex. The action of the HPA axis is inhibited by a negative feedback loop, in which the 
activation of glucocorticoid receptors in the hippocampus by cortisol suppresses the 
release of CRH from the hypothalamus (Sapolsky, Romero, & Munck, 2000). 
The activation of the HPA axis and the release of ACTH also stimulates the 




the episodic release of cortisol (Rosenfeld et al., 1971). It has been hypothesized that 
adrenal DHEA(S) may not be exclusively controlled by ACTH; while ACTH is the 
primary regulatory factor of DHEA(S), other unknown factors may also be implicated in 
its secretion (Goodyer, 2007; McKenna, Fearon, Clarke, & Cunningham, 1997), 
including differential regulation by enzyme activities downstream from ACTH 
(Hucklebridge, Hussain, Evans, & Clow, 2005). Evidence also suggests that while 
cortisol may exhibit more variability within and across days, DHEA(S) may reflect a 
more constant and stable indicator of underlying adrenal steriodogenic capacity 
(Hucklebridge et al., 2005).  
 Although the response of the HPA axis to acute stress is generally adaptive, 
chronic cortisol release has deleterious effects (McEwen & Seeman, 1999). In particular, 
chronic activation of the glucocorticoid receptors by cortisol results in damage to 
hippocampal neurons containing glucocorticoid receptors, thus disrupting negative 
feedback sensitivity in the HPA axis. In turn, reduced inhibition of the HPA axis results 
in greater cortisol hypersecretion (Gold & Chrousos, 2002; McEwen & Seeman, 1999). 
Research indicating that DHEA(S) antagonizes the negative effects of cortisol on 
hippocampal neurons, by acting as a cortisol antagonist on glucocorticoid receptors, 
suggests that it functions as a neuroprotective agent in the brain and may thereby 
decrease the risk for pathology (Kaminska et al., 2000; Kimonides, Spillantini, 
Sofroniew, Fawcett, & Herbert, 1999). For this reason, it has been hypothesized that 
DHEA(S) may play a role in regulating homeostasis (Gallagher & Ritsner, 2009). 




the exogenous administration of DHEA(S) decreases cortisol concentrations in the 
periphery (Kroboth et al., 2003).  
 
1.2.3 Cortisol 
 As illustrated above, cortisol is a steroid hormone that plays a key role in 
regulating the physiological stress response (McEwen & Seeman, 1999). Cortisol is 
metabolized from pregnenolone in the adrenal cortex, and shows a marked circadian 
rhythm, with levels peaking approximately 30 minutes after rising in the morning and 
reaching a nadir between midnight and 4:00 am (Bhagwagar, Hafizi, & Cowen, 2005; 
Yen & Laughlin, 1998). Although there is wide individual variability in cortisol 
concentrations, within-person levels tend to remain constant (de Weerth, Zijl, & 
Buitelaar, 2003), although, cortisol begins a gradual age-related increase during the third 
decade of life (Yen & Laughlin, 1998).    
 The hypersecretion of cortisol has long been implicated in the pathophysiology of 
depression (Reiss, Hemphill, Gordon, & Cook, 1949). Evidence suggests that the 
hypersecretion of morning basal cortisol occurs in approximately 50% of depression 
cases (Plotsky, Owens, & Nemeroff, 1998) and that medication-free, depressed subjects 
secrete 25% more salivary cortisol than non-depressed subjects 30 minutes after waking 
(Bhagwagar et al., 2005). Moreover, results from a number of studies suggest that 
recovered individuals with an MDD history show evidence of increased salivary cortisol 
(E Young, Aggen, Prescott, & Kendler, 2000), and an increased cortisol awakening 




2009), compared to individuals without a past history of depression. In addition, results 
from prospective studies suggest that the CAR precedes and predicts MDD twelve 
months prior to its onset in women and adolescents of both sexes (Goodyer, Tamplin, 
Herbert, & Altham, 2000; Harris et al., 2000) and increased cortisol concentrations have 
been shown in young people with a familial risk for MDD (Mannie, Harmer, & Cowen, 
2007). Taken together, the literature is unclear if increased cortisol represents a marker of 
vulnerability, a correlate, or a consequence of MDD (E Young et al., 2000). 
 In addition, not all studies have observed cortisol hypersecretion in individuals 
with MDD, suggesting that cortisol hypersecretion may not reflect a "core characteristic" 
of MDD (Peeters, Nicolson, & Berkhof, 2004; Strickland et al., 2002). Indeed, results 
from a recent large meta-analysis (20 case-control studies with 1354 MDD patients and 
1052 controls), suggests that salivary cortisol is "unable to discriminate between persons 
with and without depression" (Knorr, Vinberg, Kessing, & Wetterslev, 2010). 
Specifically, results indicated that the established relationship between salivary cortisol 
and MDD might be due to random error, including participant age and the intra-assay 
variability of salivary assay kits. The authors also theorized that HPA axis disturbance in 
MDD may be specific to severely ill inpatients versus outpatients and therefore, that the 
usefulness of cortisol as a marker for MDD may be limited to a more severe population. 
 Since cortisol is involved in the regulation of many neural circuits, HPA axis 
hyperactivity may have negative effects on a number of cognitive domains, with resulting 
implications for emotional/cognitive processing in MDD (Erickson, Drevets, & Schulkin, 




overactivity of the amygdala by elevating glucose metabolism. Overactivity of the 
amygdala may, in turn, influence perception, memory, and the experience of emotion, 
with the potential effect of increasing attention towards negative emotional stimuli 
(Suslow, Junghanns, & Arolt, 2001). Evidence also suggests that elevated levels of 
cortisol may lead to reductions in serotonin-1A (5-HT1A) receptor distribution in the 
hypothalamus, with resulting negative effects on mood states. Indeed, complex 
interactions exist between the HPA axis and the serotonin-system (Mikkelsen, Hay-
Schmidt, & Kiss, 2004); specifically, cortisol and DHEA(S) regulate serotonin 
neurotransmission by regulating 5-HT1A receptor distribution in the hypothalamus. 
Moreover, the hypothalamic 5-HT1A receptor influences HPA axis activity by modulating 
CRH and ACTH release, which affect levels of both cortisol and DHEA(S) (Moser et al., 
2010). Additionally, central effects of elevated levels of cortisol include interactions with 
the noradrenergic system, which may negatively impact the processing of emotional 
memories (Quirarte, Roozendaal, & McGaugh, 1997). 
 The potential negative effects on mood that are implicated in HPA axis 
hyperactivity may have a resulting impact on sexual function. In particular, the 
information processing model of sexual response suggests that while the genital sexual 
response relies on the automatic processing of sexual stimuli, subjective sexual response 
relies on controlled processes that are affected by central pathway function (Janssen, 
Everaerd, Spiering, & Janssen, 2000; Spiering & Everaerd, 2007). In other words, sexual 
feelings such as desire and subjective feelings of sexual arousal may depend on the 




women with MDD, increased attention towards negative stimuli as a result of cortisol 
hyperactivity may lead to lowered desire and subjective sexual arousal, while potentially 
having little impact on physiological (genital) sexual response. 
 As well as central effects on mood, a large body of evidence indicates that cortisol 
hypersecretion has inhibitory effects on hormonal secretion from HPG axis, which is 
involved in the control of reproduction and sexual response at the peripheral level 
(Schweiger et al., 1999). In particular, HPA axis hyperactivity results in increased 
concentrations of CRH and glucocorticoids, which suppress the release of hypothalamic 
gonadotropin-releasing hormone, and pituitary luteinizing hormone and follicle 
stimulating hormone (Chrousos et al., 1998; Kalantaridou et al., 2004). In turn, lowered 
concentrations of HPG axis hormones result in lowered synthesis of sex steroids in the 
ovaries, potentially having a negative impact on peripheral sexual function (Goldstein et 
al., 2004).  Moreover, since the HPG axis regulates central neurosteroid production 
through a feedback loop, it is plausible that HPG axis disruption may result in potential 
negative effects on sexual function and mood at the central level (Chrousos et al., 1998; 
Kalantaridou et al., 2004; Steiner et al., 2003).  
 
1.2.4 DHEA(S) 
 DHEA(S) are the most abundant steroids in humans (Burger, 2002), and as well 
as modulating the cortisol response to stress, express positive effects on sexuality (Labrie, 
Belanger, & Simard, 1995). DHEA-S is primarily synthesized from pregnenolone in the 




the ovaries (20%), and from circulating DHEA-S (30%) (Longcope, 1986). Like cortisol, 
levels of DHEA(S) are highly variable among women (Labrie, 2010), but show a weaker 
circadian rhythm. Whereas cortisol levels show a gradual increase with age (Yen & 
Laughlin, 1998), levels of DHEA(S) gradually decline, so that at menopause, DHEA(S) 
levels in women have decreased by approximately 60% from early adulthood (Labrie, 
2010).  
 In the periphery, DHEA(S) provides a large precursor reservoir for the synthesis 
of testosterone, dihydrotestosterone and estradiol in peripheral target tissues (e.g. brain, 
skin, liver, breast, and adipose) (Labrie, 2001). In particular, by a process known as 
intracrinology, inactive DHEA(S) is synthesized into sex steroids that exhibit their 
actions in the same cells with minimal release into circulation (Labrie, 2001). The latter is 
an important pathway of steroid production, accounting for 50% of the androgens and 
estrogens before menopause, and 75% of the androgens and 100% of the estrogens after 
menopause (Labrie, Martel, & Balser, 2011). Current research also indicates that 
DHEA(S) may have its own receptors on endothelial cells and may enhance endothelial 
function through the increased synthesis of nitric oxide (Liu & Dillon, 2004). Since nitric 
oxide is involved in mediating the relaxation of the clitoral smooth muscles that regulate 
clitoral and vaginal vasocongestion (Munarriz, Kim, Kim, Traish, & Goldstein, 2003), it 
is feasible that DHEA(S) may play a direct role in facilitating female sexual arousal 
responses (Lee et al., 2009). Indeed, results from a recent study demonstrated relaxation 
of the clitoral cavernosal smooth muscle in rabbits by DHEA(S) (Lee et al., 2009). Taken 




negative impact on female sexual function through the reduced synthesis of sex steroids 
and decreased facilitation of nitric oxide synthesis (Munarriz et al., 2003). 
 In addition to peripheral effects on sexual function, DHEA(S) are neuroactive 
steroids, either synthesized in the brain or arriving from the periphery (Gartside, Griffith, 
Kaura, & Ingram, 2010). As in the periphery, central DHEA(S) may be converted into 
sex steroids and exert effects on steroid hormone receptors that are widely located 
throughout the brain, with potential effects on sexual arousal, motivation, and receptive 
behavior (Genazzani, 2008). Moreover, although no nuclear steroid receptors for 
DHEA(S) have been identified, central DHEA(S) modulates the actions of many 
receptors involved in the regulation of mood, including the serotonin-1A receptor (5-
HT1A) (Moser et al., 2008), the γ-aminobutyric acid type A (GABAA) receptor (Gartside 
et al., 2010), the N-methyl-D-aspartate (NMDA) receptor, and the sigma subtype 1 (σ1) 
receptor (Maninger, Wolkowitz, Reus, Epel, & Mellon, 2009). In addition to the above-
mentioned regulation of the 5-HT1A receptor in the hypothalamus, in vitro studies 
demonstrate that DHEA(S) may reduce GABAA receptor-mediated inhibition of 5-HT 
neuronal firing, thus enhancing 5-HT neurotransmission and, in turn, potentially 
enhancing mood (Gartside et al., 2010). Furthermore, through its role as a σ1 receptor 
agonist, DHEA(S) has been shown to potentiate glutamate NMDA receptor function 
(Baulieu & Robel, 1998), with resulting implications for effects on mood (Feyissa, 
Chandran, Stockmeier, & Karolewicz, 2009). Therefore, it is possible that low 




desire and sexual arousal, directly through the effect of reduced sex steroid synthesis, and 
indirectly through effects on mood. 
 
1.3 Assessing the Cortisol/DHEA(S) Ratio 
1.3.1 The Cortisol/DHEA(S) Ratio 
 The importance of assessing the cortisol/DHEA(S) ratio, compared to absolute 
steroid concentrations, may be best understood in the context of anabolic balance, which 
refers to the ratio of catabolic to anabolic hormones (Maninger et al., 2009). While 
catabolic hormones such as cortisol break down metabolic compounds to produce energy, 
anabolic hormones including DHEA(S) promote growth and repair (Wolkowitz, Epel, & 
Reus, 2001). Anabolic balance is an important indicator of health and well-being, and a 
low anabolic balance (high cortisol/DHEA(S) ratio) is thought to result in dysregulation 
across many physiological systems (McEwen & Seeman, 1999). Moreover, determining 
anabolic balance is difficult from assessing absolute measures of cortisol or DHEA(S), 
given high individual variability in steroid hormone concentrations (de Weerth et al., 
2003; Labrie, 2010). Indeed, studies investigating cortisol and DHEA(S) concentrations 
in various pathologies often do not observe group differences in levels of cortisol or 
DHEA(S); however, these same studies may report group differences in the 





1.3.2 Assessing Cortisol/DHEA(S) Ratio: Depression 
  Similar to cortisol, studies assessing DHEA(S) concentrations in depression have 
reported inconsistent results. While many studies show DHEA(S) levels negatively 
correlated with depression (Barrett-Connor, Von Mühlen, Laughlin, & Kripke, 1999; 
Markianos, Tripodianakis, Sarantidis, & Hatzimanolis, 2007; Michael et al., 2000; 
Schmidt, Murphy, Haq, Danaceau, & St Clair, 2002), not all studies replicate these 
results, showing higher or unaltered DHEA(S) in individuals with depression, compared 
to control subjects without depression (Assies et al., 2004; Hsiao, 2006; Morrison, 
Freeman, Lin, & Sammel, 2011).  
 Given the ability of DHEA(S) to regulate glucocorticoid activity in the brain 
(Kaminska et al., 2000), many recent studies have placed an emphasis on assessing the 
cortisol/DHEA(S) ratio in depression (Gallagher & Ritsner, 2009; Goodyer et al., 2001). 
Compared to controls without depression (N = 41), basal cortisol/DHEA(S) ratios (i.e., 
cortisol/DHEA(S) ratios assessed at 8:00 A.M.) were significantly elevated in 
medication-free individuals with MDD (N = 39), and evening cortisol/DHEA(S) ratios 
were positively correlated with the length of depressive episode; however, no group 
differences were observed for cortisol or DHEA(S) (H. Young et al., 2002). Similarly, 
higher basal and evening cortisol/DHEA(S) ratios were observed in medicated MDD 
patients (N = 44), when compared to remitted patients (N = 35) and controls (N = 41) 
(Michael et al., 2000). In a community-based study of adolescent boys, persistently 
depressed cases (N =11) had an elevated basal cortisol/DHEA(S) ratio when compared to 




cortisol/DHEA(S) ratio predicted the persistence of the disorder (Goodyer et al., 2003). 
More recently, higher basal cortisol/DHEA(S) ratios were observed both upon admission 
and discharge in patients with treatment-resistant chronic MDD (N = 28), when compared 
to healthy controls (N = 40) (Markopoulou et al., 2009). Two studies have failed to 
observe a difference in the cortisol/DHEA(S) ratios between depressed patients and 
controls, the first in a small sample (N = 23) of depressed outpatients (Takebayashi et al., 
1998), and the second in a sample of elderly depressed patients (N = 60) (Fabian, Dew, 
Pollock, & Reynolds, 2001). However, it is feasible that methodological problems (i.e., 
small sample size, age of participants) may have influenced the outcomes of the latter 
two studies. Taking these results together, it is plausible that elevation of the basal 
cortisol/DHEA(S) ratio may be a state marker of depression (Goodyer et al., 2003; 
Markopoulou et al., 2009; Michael et al., 2000; Osran et al., 1993; H. Young et al., 2002), 
and may positively correlate with the length and persistence of depressive episodes 
(Goodyer et al., 2003; H. Young et al., 2002).  
 
1.3.3 Assessing Cortisol/DHEA(S) Ratio: Sexual Dysfunction 
 Supporting the role of DHEA in female sexual function, a number of studies have 
observed associations between low DHEA(S) and FSD. In an age-matched comparison of 
women with and without low libido (N = 80), significant differences were shown for both 
pre and postmenopausal women in levels of DHEA(S) and T (Turna et al., 2005). 
Moreover, low levels of DHEA(S) and T were positively correlated with measures of 




associations between low DHEA(S) and T in a small group (N = 32) of healthy 
premenopausal women reporting complaints of sexual dysfunction when compared to 
women without sexual difficulties.  
 Two other studies have observed association between low levels of DHEA(S) and 
FSD, but have not observed low levels of T. In particular, Basson et al. (2010) compared 
total androgen activity in women with and without HSDD (N = 245), revealing 
significantly lower levels of DHEA(S) in women with HSDD, while observing no 
difference in levels of T. Similarly, results from a  community-based, cross-sectional 
study (N = 1021) observed significant associations between low DHEA(S) and low 
sexual desire, sexual arousal, and sexual responsiveness in women aged 18 to 44 (S. 
Davis et al., 2005). Similar to the former study, no differences in levels of T were 
observed. In an attempt to make sense of this paradox (i.e., DHEA(S) is a precursor to T, 
therefore suggesting that lowered DHEA(S) would result in lowered T), the authors (S. 
Davis et al., 2005) conjectured that the lack of significant results may be due to 
complexities of assessing T. In particular, since T may be synthesized and utilized 
intracellularly from DHEA(S) (Labrie, 2001), hormonal assays may not reflect total T 
production, resulting in difficulties in interpretation (S. Davis et al., 2005). However, 
since Basson et al. (2010) assessed androgen metabolites, which reflect levels of 
intracellular T, and observed no differences between women with and without HSDD, it 
is possible that the wide range of individual hormonal levels may have accounted for the 
lack of significant findings for T. It is also feasible that DHEA(S) may exert direct effects 




steroids (e.g., estrogens) at both at the central and peripheral levels and through influence 
on NO synthesis.  
 To our knowledge, no studies have yet investigated waking cortisol levels or the 
cortisol/DHEA(S) ratio in women with FSD. Given women’s high individual variability 
in DHEA(S) concentrations, and evidence that women with low levels of DHEA(S) often 
report satisfactory sexual function (Basson et al., 2010), it is feasible that the assessment 
of the cortisol/DHEA(S) ratio may provide a more accurate hormonal assessment of 
women’s sexual function than the absolute measure of DHEA(S) (Basson et al., 2010; 
Hamilton & Meston, 2010). Although the cortisol/DHEA(S) ratio was not calculated in 
the previously mentioned study by Guay et al. (2004), women with complaints of FSD, 
but not depression, had higher cortisol levels than control women, although results did 
not reach significance, (p = .10), suggesting that women with FSD may have had a higher 
cortisol/DHEA(S) ratio than women without dysfunction. Another recent study calculated 
the cortisol/DHEA(S) ratio pre-exposure to erotic video in sexually functional women, 
observing no association with physiological or subjective sexual arousal, however, the 
basal cortisol/DHEA(S) ratio was not calculated (Hamilton & Meston, 2010). The results 
of this same study showed women’s cortisol/DHEA(S) ratio assessed post-exposure to 
erotic video negatively associated with physiological sexual arousal (i.e., vaginal pulse 
amplitude) during the erotic video. Since vaginal pulse amplitude is an indicator of 
female physiological sexual arousal, the authors suggested that the positive benefits 
associated with a low cortisol/DHEA(S) ratio may be relevant to physiological sexual 




versus indirect effects (i.e., secondary effects through mood) of a high cortisol/DHEA(S) 
ratio may potentially be relevant for female sexual function. 
 
1.4 DHEA Replacement Therapy 
1.4.1 Effects on Endogenous Hormone Levels 
Supporting the negative implications of a high cortisol/DHEA(S) ratio in MDD 
and FSD, a number of studies have reported significant positive benefits from the oral 
administration of DHEA (Traish et al., 2011). Results from across studies indicate that 
the long-term administration of DHEA in doses as small as 10 mg daily in 
postmenopausal women increase levels of DHEA and levels of all the major sex steroids 
including the androgens, estrogens, and progesterone, while decreasing levels of cortisol 
(Genazzani et al., 2006; Pluchino et al., 2008; Stomati et al., 2000). 
 
1.4.2 DHEA Replacement Therapy: Depression 
 The few clinical trials for DHEA replacement therapy in MDD have shown 
consistent improvement in symptoms of depression, supporting its role as a potential 
antidepressant (Maninger et al., 2009). It is feasible that the antidepressant effects 
attributed to DHEA may be related to its anti-glucocorticoid effects (Kaminska et al., 
2000). Moreover, and not unrelated, the antidepressant effects of DHEA may also be 
associated with central effects on 5-HT1A, GABAA, NMDA, and σ1 receptors as 
reviewed above (Belmaker & Agam, 2008). Results from a double-blind, placebo-




of DHEA or placebo for six weeks, indicated statistically significant antidepressant 
effects for DHEA (Wolkowitz et al., 1999). Nearly half of the DHEA treated patients 
showed greater than 50% improvement in ratings of depression, while none of the 
placebo-treated patients reported improvement. Similarly, results from a double-blind, 
crossover, placebo-controlled study in men and women (N = 15) with dysthymia revealed 
a 60% treatment response rate in symptom improvement for subjects treated daily for 6 
weeks with 90-450 mg of DHEA versus placebo (Bloch, Schmidt, Danaceau, Adams, & 
Rubinow, 1999). Lastly, another double-blind placebo-controlled trial (N = 46), utilizing 
the same treatment design, reported significant antidepressant effects, results showing a 
45% response rate for subjects treated with DHEA compared to a 12.5% response rate for 
placebo (Schmidt et al., 2005).  
 
1.4.3 DHEA Replacement Therapy: Sexual Dysfunction  
 While the exogenous administration of DHEA has been shown to improve 
symptoms of depression (Maninger et al., 2009), studies that have investigated the effects 
of the long-term administration of DHEA on FSD, have reported inconsistent results (S. 
Davis, Panjari, & Stanczyk, 2011). Baulieu et al. (2000) assessed the effects of DHEA 
administration in women (N = 140) with a mean age of 70, observing increased libido as 
measured by a visual-analog scale. In addition, Schmidt et al. (2005) assessed the 
administration of DHEA in depressed women (N = 23) with a mean age of 49, finding 
significant improvement in sexual desire, arousal, interest, and fantasy (Derogatis 




Four studies, conducted in postmenopausal women, revealed no effect for DHEA on 
sexual function, but were hampered by inadequate sample sizes (Morales, Nolan, Nelson, 
& Yen, 1994; Mortola & Yen, 1990; Wolf et al., 1997), by the advanced age of the 
participants (mean age of 68) (Kritz-Silverstein, Von Mühlen, Laughlin, & Bettencourt, 
2008; Wolf et al., 1997), by the use of non-validated instruments (Mortola & Yen, 1990; 
Wolf et al., 1997), and by supraphysiological levels of DHEA (Morales et al., 1994; 
Mortola & Yen, 1990). Panjari et al.(2009) utilizing an adequate sample size (N=85) and 
a validated measure (Sabbattsberg Sexual Self -Rating Scale), observed no improvement 
in sexual function in postmenopausal women experiencing a loss of sexual interest, 
compared to placebo.  
 
1.5 Current Study Aims 
 The literature suggests that a high cortisol/DHEA(S) ratio may have a negative 
impact on women’s sexuality and may be a biological mechanism that offers explanation 
for the observed comorbidity between MDD and FSD. The high comorbidity between 
these disorders, the lack of studies investigating sexual dysfunction in women with MDD, 
and the lack of treatment for women with comorbid MDD and FSD emphasize the 
importance of investigating the roles of cortisol, DHEA(S), and the cortisol/DHEA(S) 
ratio in the sexual function of women with MDD. Moreover, preliminary evidence 
regarding the possible efficacy of DHEA replacement therapy has potentially important 
clinical implications, stressing the need for further clarification of the mechanisms by 





1.5.1 Pilot Study 
A small pilot study was conducted with the aim of investigating the diurnal patterns 
of cortisol, DHEA, and the cortisol/DHEA ratio to determine the optimum time of day to 
collect salivary samples for the main study.  
 
1.5.2 Main Study 
The main study had three primary aims. The first aim was to investigate group 
differences in concentrations of cortisol, DHEA and the ratio between cortisol and DHEA 
in women with and without a history of MDD to determine the associations between 
hormones and MDD history. In particular, this aim sought to determine if a higher 
cortisol/DHEA ratio would be associated with MDD history. The second study aim was 
to investigate the relationships between hormone levels and various domains of sexual 
function to determine the overall associations between hormones and sexual function. 
Specifically, this aim sought to determine if a higher cortisol/DHEA ratio would be 
associated with lower sexual function. Lastly, the third aim of the study was to determine 
if a high cortisol/DHEA ratio would distinguish women with a history of MDD and lower 
sexual function from non-MDD women with lower sexual function. Specifically, this aim 
sought to investigate if potential associations between a higher cortisol/DHEA ratio and 
lower sexual function would be greater for women with a history of MDD. Investigating 
the predictive effects of the cortisol/DHEA ratio was the main aim of this study; 








1.6.1 Pilot Study  
Based on prior evidence showing that cortisol and DHEA exhibit a significant 
decline over the course of the day (Hucklebridge et al., 2005), and limited evidence 
suggesting that the cortisol/DHEA ratio also exhibits a diurnal slope and is significantly 
higher at 8:00 AM than at 8:00 PM (H. Young et al., 2002), I hypothesized that the 
optimum time to collect salivary samples for the Main Study would be upon waking in 
the morning.  
 
1.6.2 Main Study 
Given results from prior studies implicating the cortisol/DHEA(S) ratio in MDD 
(Markianos et al., 2007; Plotsky et al., 1998; H. Young et al., 2002), I first hypothesized 
that women with a history of MDD would have a higher cortisol/DHEA ratio when 
compared to women without a history of MDD. My second hypothesis, based on studies 
associating low concentrations of DHEA with lower sexual function in the domains of 
sexual desire, sexual arousal, and sexual response (Basson et al., 2010; S. Davis et al., 
2005), posited that a higher cortisol/DHEA ratio would be associated with lower sexual 
function. Lastly, given the high comorbidity between MDD and FSD (Clayton et al., 




mechanisms in which a high cortisol/DHEA ratio in MDD could negatively impact 
sexual function (Basson et al., 2010), I hypothesized that the relationship between the 
cortisol/DHEA ratio and sexual function would be moderated by group status (MDD 
history versus control), so that the relationship between the cortisol/DHEA ratio and 
lower sexual function would be greater for women with history of MDD, when compared 





2  CHAPTER 2: METHODS 
2.1 Pilot Study 
This pilot study was designed to provide information regarding the diurnal patterns 
of cortisol and DHEA secretion to determine the diurnal pattern of the calculated 
cortisol/DHEA ratio (C/D Ratio). Participants collected saliva samples over the course of 
a single day for later assessment of hormone concentrations.  
 
2.1.1 Participants 
Participants were recruited via word of mouth among women working as research 
assistants at the Sexual Health Research Clinic (SHRC). Inclusion criteria included 
having a normal sleep-wake cycle (waking between approximately 6:00 AM- 9:00 AM) 
to control for impact of time of waking on cortisol secretion (Federenko et al., 2004).  
 
2.1.2 Measures 
2.1.2.1 Salivary sampling. 
Each participant provided saliva samples for later assessment of cortisol and 
DHEA concentrations via salivary enzyme immunoassay. Women were instructed to 
collect saliva samples four times over the course of a single day. Specifically, samples 
were collected after waking, at 12:00 PM, 4:00 PM, and 8:00 PM. Collection times were 
based on prior studies that have explored the diurnal patterns of cortisol and DHEA 
secretion (Hucklebridge et al., 2005). Women were provided instructions for salivary 




were instructed: “Allow saliva to pool in the mouth. With head tilted forward, drool into 
the straw and collect saliva in the vial.” Participants were also advised to avoid alcohol 
12 hours before sample collection, to avoid eating or drinking anything but water 60 
minutes prior to sample collection, and to rinse mouth with water 20 minutes prior to 
sample collection. 
 
2.1.2.2 Salivary assays. 
 Salivary samples were analyzed by enzyme immunoassay using Salimetrics© kits 
for cortisol and DHEA on one occasion. Samples were frozen at -80°C immediately after 
collecting the samples from the participants until the time of analysis. Assays were 
conducted in the SHRC at the University of Vermont according to manufacturer’s 
instructions (Salimetrics, State College, PA, USA) (Salimetrics, 2005). The intra-assay 
coefficient of variation for cortisol was 10.78%. Detection limit for the cortisol assays 
was 0.007 ug/dl. The intra-assay coefficient of variation for DHEA was 16.45 %. 
Detection limit for the DHEA assays was 5 pg/ml. Prior to calculating the C/D Ratio, 
cortisol and DHEA values were converted into nmol/L.  
 
2.1.3 Procedures  
Women interested in participating in the study contacted the study PI who assessed 
for study eligibility. Informed consent was not required by the IRB since the participants 
all worked as research assistants in the SHRC. Women who were eligible to participate in 




collection of saliva, the saliva collection device (collection vials and straws), and a card 
to record sampling times. Each participant chose a weekday in which to collect salivary 
samples. Participants were instructed to place the salivary samples in their home freezers 
until dropping the frozen samples off at the SHRC. 
 
2.2 Main Study 
2.2.1 Design 
This study was a cross-sectional, correlational design with hormones (cortisol, 
DHEA, C/D Ratio) as the independent variables, measures of sexual desire/arousal, 
sexual behavior, and sexual response as the outcome variables, and depression status 
(control vs. MDD history) as the potential moderating variable.  
A number of domains related to female sexual function were utilized as outcome 
variables given our limited understanding of the roles of cortisol, DHEA, and the 
cortisol/DHEA ratio in women’s sexuality (see table1). Outcome variables assessed in the 
current study included measures of sexual desire and sexual arousal, since these aspects 
of female sexuality have been most often associated with DHEA in the literature (Basson 
et al., 2010; S. Davis et al., 2005; Turna et al., 2005). Outcome variables also included 
the assessment of sexual behavior (i.e., frequency of sexual activity, sexual 
assertiveness), given that hypoactive sexual desire disorder, as defined by the DSM-IV-
TR, is characterized by the absence of sexual fantasies and/or desire for sexual activity 
(APA, 2000). The literature has also associated a lack of sexual desire and sexual arousal 




sexual assertiveness (Hurlbert, 1991). Lastly, outcome variables included measures of 
sexual response, including the assessment of psychological arousal (i.e., subjective 
feelings of sexual desire and arousal) and physiological arousal (i.e., vaginal pulse 
amplitude) to erotic stimuli.  
 
Table 1: Dependent variables utilized in the main study 
Dependent Variables  
Sexual Desire/Arousal  
Female Sexual Function Index-Desire  FSFI-Desire 
Female Sexual Function Index-Arousal  FSFI-Arousal 
Female Sexual Function Questionnaire-Desire  FSFQ-Desire 
Female Sexual Function Questionnaire-Arousal  FSFQ-Arousal 
Sexual Behavior  
Brief Index of Sexual Functioning-Frequency  BISF 
Hurlbert Index of Sexual Assertiveness HISA 
Sexual Response (to erotic video)  
Sexual Arousal and Desire Inventory-Pre Video Pre-SADI 
Sexual Arousal and Desire Inventory-Post Video Post-SADI 
Maximum Subjective Arousal Sub-Max 
Vaginal Pulse Amplitude VPA% 
 
 
To explore the potential moderating effect of Group (MDD history vs. controls) 
on the relationship between hormones and sexual outcome variables, two groups of 
women (an MDD history group and a control group), each consisting of women with a 
range of sexual function (assessed by a continuous measure), collected saliva samples 




group status and to assess sexual outcome variables, women scheduled a visit at the 
SHRC to participate in a structured clinical interview, complete questionnaires on sexual 
function, and participate in a psychophysiological assessment.  
 
2.2.2 Participants  
 Participants were recruited through advertisements in local newspapers, through 
flyers posted at the University of Vermont, local wellness clinics, gathering spots, coffee 
shops, and through Craig’s List. Participants were also recruited in select psychology 
classes at the University of Vermont. Recruitment for the MDD history group targeted 
women experiencing feelings of depression with or without sexual problems, while 
recruitment for the control group targeted women with or without sexual problems.  
 Inclusion criteria for the control group included a lack of current or past MDD as 
assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) 
(First, Spitzer, & Williams, 2002). In addition, an initial attempt was made to recruit an 
equal number of women in the control group with and without FSD in the domains of 
desire and/or arousal (as assessed by the Abbreviated Female Sexual Function 
Questionnaire (AFSFQ) during the phone screening). However, given the difficulty of 
recruiting women with FSD, study criteria were adjusted to include women with a range 
of sexual function (as assessed during the study by the Female Sexual Function Index 
(FSFI)). 
Inclusion criteria for the MDD history group included meeting current or past 




episodes were included in the study given research indicating that patients in remission 
from depression have significantly elevated cortisol when compared with controls (Aubry 
et al., 2010; Bhagwagar et al., 2003; Vreeburg et al., 2009; E Young et al., 2000). Similar 
to the control group, an attempt was made to recruit an equal number of women with and 
without FSD; however, due to recruitment difficulties, the MDD history group included 
women with a range of sexual function. Women currently receiving non-pharmacological 
treatment for MDD were also included in the MDD history group, since it was not 
expected that these treatments would impact women’s MDD status over the 4 days of the 
study. 
 Inclusion criteria for both groups included being between the ages of 20 and 45 
and being premenopausal. The minimum age of 20 was chosen to ensure maturity of 
sexual function (Hayes, Dennerstein, Bennett, & Fairley, 2008), while the maximum age 
of 45 was chosen to control for the age-related increase in cortisol and decline in DHEA 
(Yen & Laughlin, 1998). Women were premenopausal given the association of the 
menopausal transition with depression (Freeman et al., 2004) and the potential effects of 
menopause on sexual function (Dennerstein & Hayes, 2005). Further inclusion criteria for 
both groups included (1) engaging in sexual activity within the past four weeks to ensure 
that sexual function was not associated with frequency of sexual activity (Laumann et al., 
1999), and (2) having a normal sleep-wake cycle (waking between approximately 6:00 
AM- 9:00 AM) to control for impact of time of waking on cortisol secretion (Federenko 




  Exclusion criteria for both groups included: (1) the use of hormonal 
contraceptives given potential effects on steroid levels (A. Davis & Castano, 2004; 
Wiegratz et al., 2003), (2) cigarette smoking given potential effects on steroid levels 
(Soldin, Makambi, Soldin, & O'Mara, 2011), (3) current use of prescription drugs that 
impact sexual function or steroid levels (i.e., antidepressants, anti-anxiolytics, 
antipsychotics, beta blockers, corticosteroids, androgen therapy, and allergy medications) 
(Granger, Hibel, Fortunato, & Kapelewski, 2009), (4) a body mass index less than 18.5 or 
more than 31.0 due to variable steroid concentrations (Key et al., 2003),  (5) a history of 
forced sexual experience given the association of childhood sexual abuse with impaired 
sexual function (Rellini & Meston, 2006a), (6) a history of chronic medical disease given 
negative correlates with positive sexual function (i.e., cardiovascular problems, thyroid 
problems, diabetes) (Lewis et al., 2010; Shifren et al., 2008), (7) pregnancy or 
breastfeeding during the past year due to potential effects on steroid levels related to 
increased glucocorticoid binding globulin (Granger et al., 2009), and (8) chronic sexual 
pain not relieved by a vaginal lubricant as assessed by the AFSFQ, since these problems 
may interfere with feelings of sexual arousal and desire. In addition, women with a 
comorbid diagnosis of posttraumatic stress disorder (PTSD) as assessed by the SCID-1 
were excluded, since PTSD is associated with differential patterns of HPA axis activity 
when compared to MDD (Handwerger, 2009; Yehuda, Brand, Golier, & Yang, 2006). 
Lastly, women with a history of Bipolar 1 or Bipolar 2 Disorder, current substance use 
disorders, current eating disorders, and/or acute, serious suicidal intent were excluded 




2.2.3 Equipment and Measures  
2.2.3.1 Structured Clinical Interview for DSM-IV-TR (SCID-I). 
 The SCID-I (First, Spitzer, & Williams, 2002) is a structured clinical interview 
that was utilized during the initial phone screening and the scheduled SHRC appointment 
to assess for Axis I disorders as defined in the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (APA, 2000). In 
particular, the Mood Episodes Module and the PTSD section of the Anxiety Module were 
administered to potential participants during the phone screening to assess for MDD, 
PTSD, and suicidal intent. In addition, the SCID Screener was administered during the 
phone interview to screen for potential substance-related disorders, eating disorders, and 
comorbid diagnoses. Positive responses to questions related to substance use and eating 
disorders were followed with administration of the Substance Use Disorders and/or the 
Eating Disorders Modules. During the SHRC visit, the entire SCID-I was administered to 
participants to confirm the diagnoses received during the phone screening and to assess 
for further Axis I diagnoses. In addition, the number of major depressive episodes (MDE) 
and comorbid Axis 1 diagnoses were assessed to code for study sample characteristics. 
The PI has been trained to administer the SCID-1 with individuals with psychological 
difficulties including depression and suicidal ideation. The administration of the SCID by 





2.2.3.2 Questionnaires.  
2.2.3.2.1 MacArthur Salivary Questionnaire. 
 The MacArthur Salivary Questionnaire (Stewart & Seeman, Retrieved July 2000) 
was administered to participants by a research assistant. This questionnaire follows the 
MacArthur Research Network’s guidelines for salivary cortisol measurement by 
assessing various daily life experiences that have been shown to alter cortisol secretion 
(Nicolson, 2008). Specifically, participants were asked to provide information regarding 
time since awakening, degree of pressure of daily stress, daily exercise, and compliance 
with study requirements regarding consumption of nicotine, caffeine, and alcohol, and the 
use of recreational drugs and/or medicines.  
 
2.2.3.2.2 Demographics Questionnaire. 
 Participants completed a questionnaire designed for the current study to assess the 
demographic characteristics of the study sample. Items assessed included age (Shifren et 
al., 2008), education (Shifren et al., 2008), race/ethnicity (Laumann et al., 1999; Woo, 
Morshedian, Brotto, & Gorzalka, 2012), relationship status (Hayes, Dennerstein, Bennett, 
Sidat, et al., 2008), length of relationship (McCabe & Goldhammer, 2012), past history of 
hormonal contraceptive use (Panzer et al., 2006), medical history, and height and weight 
(Key et al., 2003). Body mass index (BMI) was calculated from the height and weight 
obtained from this questionnaire. In addition, the sexual orientation of the participants 
was assessed with the Kinsey Scale (Kinsey, Pomeroy, & Martin, 1948), a 7-point Likert-




2.2.3.2.3 Female Sexual Function Index (FSFI). 
 The FSFI (Rosen et al., 2000) was administered to participants to provide a 
continuous measure of overall sexual function (FSFI-Total), which was utilized to 
operationalize sexual function for the current study. The FSFI also provided specific 
measures of sexual function in the domains of desire (FSFI-Desire) and arousal (FSFI-
Arousal), which were utilized as sexual function outcome variables in the analyses. FSFI-
Total was calculated by adding the scores from the six FSFI domains (Desire, Arousal, 
Lubrication, Orgasm, Global Satisfaction, and Pain). Endorsements of total FSFI scores ≤ 
26.5 indicate the likelihood for clinical levels of FSD. The FSFI has shown a high degree 
of internal consistency for each of the individual domains (Cronbach’s α =.82 –.92). The 
diagnostic accuracy of the FSFI-Desire domain has been supported for observational 
studies and clinical trials of Hypoactive Sexual Desire Disorder (Gerstenberger et al., 
2010), and the FSFI-Arousal domain has been shown to reliably discriminate between 
women with Female Sexual Arousal Disorder and control patients (Rosen et al., 2000). 
The FSFI has also demonstrated high inter-item reliability (Cronbach’s α = 0.82 – 0.92) 
and test-retest reliability (r = 0.79). Construct validity has been established by comparing 
mean difference scores between the women with Sexual Arousal Disorder and control 
groups for each of the domains (p ≤ 0.001), while divergent validity has been established 





2.2.3.2.4 Abbreviated Female Sexual Function Questionnaire (AFSFQ).  
 The AFSFQ (Quirk et al., 2002) was administered to participants to provide 
measures of sexual function in the domains of sexual desire (FSFQ-Desire) and sexual 
arousal (FSFQ-Arousal), which were utilized as sexual function outcome variables in the 
analyses. In addition, selected questions from the AFSFQ were utilized during the initial 
phone screening to assess sexual function for screening purposes. The AFSFQ is a 20-
item self-report questionnaire, consisting of a subset of questions from the Female Sexual 
Function Questionnaire (FSFQ) (Quirk, Haughie, & Symonds, 2005). This scale was 
chosen since it provides a comprehensive measure of both sexual desire and sexual 
arousal (across three distinct arousal domains). The AFSEQ contains the following 
subscales: Desire (6 items; range 5–31), Arousal-Sensation (4 items; range 4–20), 
Arousal-Lubrication (2 items; range 2–10), Arousal-Cognitive (2 items; range 2–10), 
Orgasm (3 items; range 1–15), and Pain (3 items; range 2–15). The three sexual arousal 
subscales can be totaled to provide an overall measure of sexual arousal (FSFQ-Arousal). 
Normal sexual functioning is indicated by higher scores. The FSFQ has demonstrated 
excellent internal consistency (Cohen's weighted kappa = 0.65 to 0.91), moderate to good 
test-retest reliability (r = 0.42 to 0.78), and excellent discriminant validity when 
comparing women with a diagnosis of sexual dysfunction to women without dysfunction 
(p < 0.001) (Quirk et al., 2002).  
 
2.2.3.2.5 Brief Index of Sexual Functioning-Women (BISF-W). 




levels of sexual functioning and satisfaction (Taylor, Rosen, & Leiblum, 1994). The 
BISC-W includes seven dimensions of sexual function, including a Frequency dimension 
that consists of a single eight-item scale. The Frequency dimension of the BISF-W was 
administered to participants to provide information regarding the frequency of sexual 
activity, which was utilized as a sexual behavior outcome variable (BISF). This 
dimension provided an index of the quantity and variety of sexual activity engaged in 
during the last six months. Specifically, questions assessed the frequency of kissing, 
sexual fantasy, masturbation alone, masturbation with a partner, petting, oral sex, vaginal 
sex, anal sex. Responses for each question range from 1 to 6, with higher scores 
indicating greater frequency of sexual activity (0 = not at all, 1 = once, 2 = 2 or 3 times, 3 
= once a week, 4 = 2 or 3 times a week, 5 = once a day, 6 = more than once a day). The 
overall frequency of sexual behavior was determined by summing the eight items. The 
BISF-W has demonstrated a high degree of concurrent validity with the Derogatis Sexual 
Function Inventory (Derogatis & Melisaratos, 1979), and adequate internal consistency 
and test-retest reliability. Comparison of mean scores on the Frequency dimension of the 
BISF-W has demonstrated statistically significant differences between surgically 
menopausal women with impaired sexual function and healthy women; however, the 
alpha coefficient of the frequency dimension has not been computed since it consists of a 
single eight-item scale (Mazer, Leiblum, & Rosen, 2000). 
 
2.2.3.2.6 The Hurlbert Index of Sexual Assertiveness (HISA). 




a measure of sexual assertiveness that was utilized as a sexual behavior outcome variable 
in the analyses. The HISA is a 25-question index that assesses comfort with one’s sexual 
activity, sexuality, sexual body, and ability to communicate sexually. Each statement is 
scored on a five point scale from 0 to 4, with 0 representing “all of the time” and 4 
representing “never.” The validity and reliability of the HISA has been repeatedly upheld 
in studies. The HISA demonstrated a mean test-retest reliability of .85 for clinical and 
nonclinical subjects and has satisfactory face, predictive and discriminant validity (Pierce 
& Hurlbert, 1999). 
 
2.2.3.2.7 The Beck Depression Inventory-II (BDI-II). 
 Participants completed the BDI-II (Beck, Steer, & Brown, 1996) to provide a 
continuous measure of MDD severity to be utilized as a continuous measure of current 
MDD symptomology and as a potential covariate in the analyses. The BDI-II is a self-
report measure of depression symptoms present in the past two weeks and is consistent 
with the DSM-IV criteria for depression. The BDI-II contains 21 questions, each answer 
being scored on a scale value of 0 to 3, with total scores of 0-13 suggesting minimal 
depression; scores of 14-19 suggesting mild depression; scores of 20-28 suggesting 
moderate depression; and scores of 29-63 suggesting severe depression. Individuals 
endorsing scores ≥ 20 on the BDI-II fall within the clinical range of MDD. The BDI-II 
positively correlates with the Hamilton Depression Rating Scale, r = 0.71, has a one-





2.2.3.3 Psychophysiological assessment. 
2.2.3.3.1 Stimuli: video sequence. 
 To induce sexual arousal during the psychophysiological assessment, participants 
viewed an 8-minute video sequence, which consisted of 3 minutes of non-sexual video 
(derived from a series of travel videos) and 5 minutes of sexually explicit video (female 
directed videos consisting of foreplay, oral sex, and vaginal intercourse among 
heterosexual couples). The type and length of the video utilized has been shown to 
increase physiological and subjective sexual arousal in women of various sexual 
orientations during laboratory studies (Rellini & Meston, 2006b). 
 
2.2.3.3.2 Subjective sexual arousal. 
Subjective sexual arousal was assessed during the video sequence with the 
Arousometer. The Arousometer is a sliding lever moved by the participant to indicate her 
level of sexual arousal during exposure to the video sequence to provide a continuous 
measure of subjective sexual arousal. The lever was placed on the arm of the reclining 
chair and the participant was instructed to move it to indicate her level of sexual arousal 
(on a scale from 0 to 10) while watching the videos. Data for subjective sexual arousal 
was collected using ACQKnowledge version 3.91 software (Biopac Systems, Inc. Santa 
Barbara, CA®), and a data acquisition unit Model MP150 (Biopac Systems, Inc., Santa 
Barbara, CA®). The same procedure has been used in prior studies and has shown 




measure of maximum sexual arousal was calculated based on the highest data point 
during the sexual segment of the video (Sub-Max). 
 
2.2.3.3.3 Sexual Arousal and Desire Inventory (SADI). 
 Subjective sexual desire and arousal in response to the erotic video was assessed 
with the administration of the Sexual Arousal and Desire Inventory (SADI) (Toledano & 
Pfaus, 2006) before and after the video sequence. The SADI is a 54-item scale that uses 
descriptors rated along a 6-point Likert scale to form four sub-factors that evaluate 
physiological, cognitive-emotional, motivational, and aversive-inhibitory components of 
the subjective experience of sexual desire and arousal. Total scores on the Pre-SADI and 
Post-SADI sub-factors [SADI- Physiological (SADI-P), SADI-Evaluative (SADI-E), 
SADI-Motivational (SADI-M), and SADI-Aversive (SADI-A)] were utilized as 
continuous outcome measures of subjective sexual desire/arousal. The SADI and its 
subscales have demonstrated excellent reliability (Cronbach’s α = 0.71 – 0.91). The 
SADI has shown strong convergent validity with other scales measuring the same 
constructs and discriminant validity with scales that do not measure levels of sexual 
arousal, desire, or affect, including The Beck Depression Inventory (Toledano & Pfaus, 
2006).  
 
2.2.3.3.4 Physiological sexual arousal. 
 Physiological sexual arousal was assessed during the video sequence with a 




pulse amplitude (VPA) from the non-sexual to the sexual segments of the video, which 
was utilized as a continuous outcome measure of physiological sexual arousal (VPA%). 
The vaginal photoplethysmograph is a small, plastic tampon-shaped device containing a 
small red light and a light detector, which is inserted into the vagina by the participant. 
Data for physiological sexual arousal was collected using ACQKnowledge version 3.91 
software (Biopac Systems, Inc. Santa Barbara, CA®), and a data acquisition unit Model 
MP150 (Biopac Systems, Inc., Santa Barbara, CA®). During the acquisition of data, the 
vaginal photoplethysmograph illuminates part of the capillary bed in the vagina, which in 
turn, absorbs some of the light and reflects the rest back. The amount of light reflected 
back is measured by the light detector in the probe. During a state of physiological sexual 
arousal, vaginal blood flow increases, resulting in greater light absorption by the 
capillaries and less reflected light. Vaginal blood flow has been demonstrated to be a 
sensitive and specific measure of genital sexual arousal. VPA is the primary outcome 
variable assessed by this methodology, with greater amplitude indicating greater vaginal 
blood volume. The VPA signal is sampled 1000 times per second and the amplitude of 
each pulse wave is recorded in millivolts (mV).  
In agreement with common procedures to clean VPA data (Prause & Janssen, 
2004), artifacts caused by movements were deleted during visual inspection of the data. 
Data were then averaged separately over the neutral and erotic video segments. Since 
women have large individual variability in genital arousal, the percent change in vaginal 
pulse amplitude from the neutral to the erotic video (VPA%) was calculated for each 




guidelines provided for sexual psychophysiological data analysis (Prause & Janssen, 
2004). The VPA% data from one woman in the current study was over three standard 
deviations from the mean and was therefore not included in the data analysis. 
 
2.2.3.4 Salivary sampling. 
 Salivary samples were collected from each participant to assess mean 
concentrations of cortisol and DHEA via salivary enzyme immunoassay. Concentrations 
of cortisol, DHEA, and the calculated cortisol/DHEA ratio were utilized as continuous 
predictor variables in the analyses (cortisol, DHEA, and C/D Ratio). The assessment of 
DHEA (vs. DHEA-S) was chosen given concerns related to assessing DHEA-S 
concentrations via salivary sampling. Although the half-life of DHEA (1-3 hours) is 
shorter than that of DHEA-S (10-20 hours) (Burger, 2002), concerns regarding blood 
contamination in the salivary assessment of DHEA-S and the need to adjust for flow rate 
when assessing DHEA-S (Vining, McGinley, & Symons, 1983), have led experts to 
recommend the assessment of DHEA vs. DHEA-S for salivary assays (Salimetrics, 
2010). Moreover, research points to a higher serum/saliva correlation for DHEA (r = 0.9) 
(Goodyer et al., 1996). A good serum/saliva correlation has also been demonstrated for 
cortisol (r = 0.6) (Goodyer et al., 1996). Salivary levels for cortisol and DHEA represent 
about 5% of levels in serum. 
The samples were collected on three consecutive days utilizing the instructions 
provided by Salimetrics for waking salivary sampling (Salimetrics, 2011). In particular, 




provided instructions for salivary sampling utilizing the “passive drool” method 
(Salimetrics, 2011). Specifically, women were instructed: “Allow saliva to pool in the 
mouth. With head tilted forward, drool into the straw and collect saliva in the vial.” To 
account for variation in the timing of sample collection related to individual waking time, 
the time of sample collection was averaged for each participant across the three days of 
collection and was utilized as a control variable in the analyses (Sample-Time).  
 Salivary samples were collected between day 8 and day 16 of the menstrual cycle 
(M = day 12) to control for potential cyclical fluctuations in cortisol (Salonia et al., 2008), 
DHEA (Symonds, Gallagher, Thompson, & Young, 2004), and /or mood (Reed, Levin, & 
Evans, 2008). A recent study reported that DHEA concentrations remain stable across the 
menstrual cycle (Salonia et al., 2008); however, results from an earlier study suggested 
that DHEA may be lowered during the luteal phase (Symonds et al., 2004). Relevant to 
cortisol, many studies show no variation across the menstrual cycle (Kudielka & 
Kirschbaum, 2003; Liening, Stanton, Saini, & Schultheiss, 2010), although other studies 
show small fluctuations (Kirschbaum, Kudielka, Gaab, Schommer, & Hellhammer, 
1999). 
 
2.2.3.5 Salivary assays. 
 Salivary samples were analyzed by enzyme immunoassay using Salimetrics© kits 
for cortisol and DHEA on two separate occasions. Samples were frozen at -80°C 
immediately after collecting the samples from the participants until the time of analysis. 




manufacturer’s instructions (Salimetrics, State College, PA, USA) (Salimetrics, 2005) 
and instructions provided during a personal communication with Doug Granger, Ph.D. 
(Granger, Schwartz, Booth, Curran, & Zakaria, 1999; Granger, Shirtcliff, Booth, 
Kivlighan, & Schwartz, 2004). In particular, given the number of samples to analyze in 
the current study, each individual sample was tested in one well and, after deleting 
outliers that were three standard deviations from the mean, the concentration values for 
each participant on each day were averaged to obtain a single value. Although this 
methodology does not provide the reliability provided by assaying the samples in 
duplicate (standard protocol), it does allow samples that were compromised to be 
discarded. To ensure the reliability of this methodology, a subset of samples were chosen 
at random to run in duplicate to indicate consistent pipetting and precision. In addition, 
standards and controls were run in duplicate per standard protocol. The intra-assay and 
inter-assay coefficients of variation for cortisol were 8.70% and 3.62 % respectively. 
Detection limit for the cortisol assays was 0.007 ug/dl. The intra-assay and inter-assay 
coefficients of variation for DHEA were 10.83% and 16.54% respectively. Detection 
limit for the DHEA assays was 5 pg/ml.  
 In line with prior studies utilizing the cortisol/DHEA(S) ratio, cortisol and DHEA 
values were converted into their respective molecule weights prior to calculating the C/D 
Ratio (Goodyer et al., 2001; Michael et al., 2000). In particular, each hormone was 
multiplied by its respective conversion factor. For cortisol (molecular weight = 362.42 
g/mol) the conversion factor from ug/dL to nmol/L is approximately 27.6. For DHEA 




0.0035. The C/D Ratio was calculated from non-transformed hormone values, however, 
after computing the ratio, Log10 transformations were conducted on cortisol, DHEA, and 
the C/D Ratio to transform skewed values. All results are reported in nmol/L.  
 
2.2.4 Procedures 
 Women interested in participating in the study contacted the SHRC via phone or 
email for a phone screening to determine their eligibility to participate in the study. The 
phone screening assessed for inclusion and exclusion criteria as outlined above. All 
phone screenings were conducted by the study primary investigator (PI) or by a trained 
research assistant to ensure compliance with the SCID-I administration. The procedures 
of the study protocol were explained to women who met study criteria and for women 
agreeing to participate, a visit to the SHRC was scheduled.  Participants were asked to 
abstain from alcohol, to limit their caffeine intake, and to refrain from intense physical 
exercise and sexual activities throughout the study period.  
 Upon arriving at the SHRC participants were presented with the informed 
consent. After receiving an explanation of the study procedures and signing the informed 
consent, participants were administered the MacArthur Salivary Questionnaire to assess 
for compliance with the study requirements. Participants were then asked to complete a 
number of self-reported questionnaires including the demographics questionnaire, the 
AFSFQ, the FSFI, the BISF, the HISA, and the BDI-II. Next, women completed the 
sexual psychophysiological assessment. During the assessment the participant sat in a 




inside. The research assistant explained how to insert and remove the vaginal 
photoplethysmograph and left the participant alone in the private room. After inserting 
the photoplethysmograph, the participant’s readiness to continue was communicated to 
the research assistant in the adjacent room via an intercom system. The research assistant 
then gave instructions for moving the Arousometer, followed by a practice session 
designed to allow familiarity with the device. Immediately before the video sequence the 
participant was asked to complete the Pre-SADI. The completion of the Pre-SADI was 
followed by exposure to the video sequence. Once the video sequence was completed, 
participants were asked to complete the Post-SADI. Participants then removed the 
photoplethysmograph and placed it in a plastic bag for later sterilization. Following the 
psychophysiological assessment, participants were administered the SCID-I to ensure 
diagnostic results from the phone screening and to assess for comorbid diagnoses. 
Participants who were in violation of study requirements (N = 2) were told that they did 
not meet criteria for the study and were compensated $20.00 for their time. 
 At the end of the appointment, participants were given instructions for completing 
salivary sampling at home over the following three days (Adam & Kumari, 2009). 
Participants were provided with a saliva sample collection kit containing instructions, the 
saliva collection device (collection vials and straws) and a card to record sampling times. 
To enhance compliance and to record sampling time, participants were asked to send a 
text message to the PI immediately upon taking the saliva sample. Participants were 




research assistant or until dropping the frozen samples off at the SHRC. Upon receipt of 





3 CHAPTER 3: ANALYTIC PLAN 
3.1 Pilot Study 
3.1.1 Repeated Measures ANOVA 
To investigate the hypothesis that cortisol, DHEA, and the C/D Ratio would 
exhibit a significant diurnal decline, three, one-way repeated measures ANOVA were 
conducted with the time of sample as the four-level factor (Waking, 12:00 PM, 4:00 PM, 
8:00 PM). Repeated measures ANOVA were followed with Bonferroni planned pairwise 
comparisons.  
 
3.2 Main Study 
3.2.1 Power Calculation 
Since there are no available data on the waking C/D Ratio in women with FSD, 
the power calculation for this study was based on data collected by Turna et al., (2005), 
which reported significant correlations between DHEA levels and sexual function (as 
assessed by the FSFI) in non-depressed women aged 21-70. Based on these data on FSFI 
scores (means and standard deviations), a power analysis (GPower 3.0.5) determined that 
a sample of 55 women would allow for a power of .80 when using correlational analyses 





3.2.2 Group Differences 
3.2.2.1 Group characteristics. 
An initial series of independent-samples T-tests were conducted to determine 
potential Group differences in Age, BMI, BDI-II, and sexual function (FSFI-Total).  
 
3.2.2.2 Relationships between hormones and Group. 
To investigate the first study hypothesis that women in the MDD history group 
would have a higher C/D Ratio when compared to women in the control group, a second 
series of independent-samples t-tests investigated potential Group differences in levels of 
hormones. 
 
3.2.3 Pearson’s Correlations 
3.2.3.1 Hormones and dependent variables. 
Next, a series of Pearson’s correlations were conducted to investigate the second 
study hypothesis that hormone values would be associated with sexual desire/arousal, 
sexual behavior, and sexual response outcome variables. Analyses were conducted in an 
exploratory fashion given the lack of literature regarding the influence of cortisol, DHEA, 
and C/D Ratio on women’s sexuality. Specifically, 3 series of correlations examined the 
relationships between hormones (cortisol, DHEA, C/D Ratio) and 1) sexual 
desire/arousal variables (FSFI-Desire, FSFI-Arousal, FSFQ-Desire, FSFQ-Arousal), 2) 
sexual behavior variables (BISF, HISA) and 3) sexual response variables (VPA%, Sub-




3.2.3.2 Study covariates. 
Pearson’s correlations were then computed to assess potential relationships 
between study covariates (Age, BMI, Sample-Time) and hormones (cortisol, DHEA, C/D 
Ratio). Pearson’s correlations also assessed potential relationships between study 
covariates (Age, BDI-II) and outcome measures. Since Age, BMI, and Sample-time are 
variables that have the potential to affect hormone concentrations (van Anders, 2012), 
these covariates were theoretically relevant to the current study and were included in all 
regression analyses. The covariate BDI-II was included in secondary regression analyses 
when theoretically relevant. 
 
3.2.4 Regression Analyses 
A series of two-step hierarchical multiple regressions were conducted to further 
explore relationships between hormones and the sexual desire/arousal, sexual behavior, 
and sexual response dependent variables identified as statistically significant in the 
correlation analyses. In particular, regression analyses allowed for the control of relevant 
study covariates that in many cases impacted the significance of the original correlations, 
either by increasing or reducing the significance of the relationships or by changing the 
relationship from significant to non-significant. In addition, regression analyses were 
chosen to allow for moderation analyses to test the interaction effect of hormones and 
Group on sexual outcome variables (hypothesis three). Regression also allowed for 
analyses testing potential mediating effects. In all models, the covariates were entered at 




the unique and additive effect of the hormones on the outcome variables when controlling 
for the covariates. 
 
3.2.5 Moderation Analyses 
A series of moderation analyses were conducted to investigate the third study 
hypothesis that Group (MDD history vs. Control) would moderate the relationships 
between hormones and sexual function outcome variables. Specifically, for regression 
models showing significant effects of hormones on dependent variables, hierarchical 
multiple regressions were conducted to test the additive effects of the interaction 
variables (hormones X Group) on the sexual response dependent variables. In all models, 
the covariates were entered at Step1, followed by the addition of hormones (cortisol, 
DHEA, or C/D Ratio) and Group at Step 2. Lastly, at Step3, the interaction effect was 
entered (hormones X Group) to test the additive effect of the interaction. Hormones and 





4 CHAPTER 4: RESULTS 
4.1 Pilot Study 
4.1.1 Participants 
Participants for this study were 7 women between the ages of 19 and 54 (M = 
25.85, SD = 12.49). 
 
4.1.2 Hormone Values 
Descriptive statistics provided concentration values for cortisol, DHEA, and the 
calculated C/D Ratio (see table 2). Visual inspection of the data showed that cortisol, 
DHEA and the C/D Ratio exhibited a decline over the course of the day.  
 
Table 2: Hormone values at four time points from waking to 8:00 PM (N = 7) 
 Waking 12:00 PM 4:00 PM 8:00 PM 
Hormones: nmol/L Mean SD Mean SD Mean SD Mean SD 
Cortisol 10.51 (5.47) 5.22 (1.23) 3.73 (1.70) 2.49 (1.19) 
DHEA .71 (.30) .43 (.14) .37 (.23) .35 (.34) 
C/D Ratio 15.58 (6.80) 13.22 (4.27) 10.95 (4.47) 9.63 (5.46) 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = Cortisol/DHEA Ratio 
 
4.1.3 Diurnal Patterns for Cortisol, DHEA, and C/D Ratio  
The diurnal profiles for cortisol, DHEA and C/D Ratio were investigated in a 
series of one-way repeated measures ANOVA, with the time of sample as a 4-level factor 
(Waking, 12:00 PM, 4:00 PM, 8:00 PM) (see figure 1). The covariate Age was included 




day as a whole, F = 11.71 (1.1, 6.6), p = .01, η2  = .66. Bonferroni tests showed a trend for 
Waking cortisol to be significantly higher than 8:00 PM cortisol (p = .06), and showed 
that 12:00 PM cortisol was significantly higher than 8:00 PM cortisol (p = .01). The 
second model conducted for DHEA also observed a significant linear trend of decline 
across the day as a whole, F = 10.24 (3, 18), p < .001, η2  = .63. Bonferroni tests indicated 
that Waking DHEA was significantly higher than DHEA at 4:00 PM (p = .05) and 8:00 
PM (p = .01), with a trend of significance for Waking DHEA to be significantly higher 
than12:00 PM DHEA (p = .07). Lastly, the third model investigated the diurnal profile 
for C/D Ratio. Contrary to results for cortisol and DHEA, a significant effect for time 
was not observed, F = 1.24 (3, 18), p = .32, η2  = .20, indicating a lack of an identifiable 
diurnal variation for C/D Ratio.  
Taken together, these results offer support for prior data (Markopoulou et al., 
2009), that revealed no effect for time in C/D Ratio assessed between 9:00 AM and 5:00 
PM. The authors suggested that DHEA may covary with cortisol in such a way that, 
while significant changes are observed in the diurnal patterns of cortisol and DHEA 
secretion, no significant effect for time is observed for C/D Ratio assessed during the 
same time period. It is also plausible that the small sample size of the present study could 
have contributed to the insignificant diurnal slope for C/D Ratio since a significant effect 
for time has been observed in at least one prior study (H. Young et al., 2002). Given that 
the current study observed no statistically significant changes in the C/D Ratio over the 
course of the day, it was determined to collect saliva upon waking, since cortisol and 







Figure 1: Patterns of mean diurnal hormone secretion for a: Cortisol b: DHEA, and 
c: C/D Ratio. Bars represent mean ± SEM. 




















































4.2 Main Study 
4.2.1 Participants 
 A total of 53 women participated in the study (25 women in the MDD history group 
and 28 women in the control group). Due to recruitment difficulties, of the 25 women 
who qualified for the MDD history group, only 3 women met DSM-IV-TR criteria for 
current MDD; the remaining 22 women met DSM-IV-TR criteria for past MDD. Women 
in the MDD history group reported a range of 1 – 16 past MDD episodes (M = 3.65).  
 Of the 637 women who called to inquire about the study, the majority of women (N 
= 547) did not qualify for numerous reasons, including history of sexual abuse (N = 80), 
smoking cigarettes within past 3 months (N = 88), the use of hormonal contraceptives 
within past 3 months (N = 92), waking time outside of study parameters (N = 38), BMI 
(N = 44), diagnosis of PTSD (N = 22), diagnosis of bipolar disorder (N = 12), no sexual 
activity during the past 4 weeks (N = 29), age < 20 (N = 2), menopause (N = 10), sexual 
pain (N = 8), pregnant/breastfeeding during past year (N = 28), taking medications during 
the past 3 months that affect sexuality (N = 52), and use of substances that may impact 
hormones (N = 42). In addition, 22 women declined study participation. Of the 68 women 
who qualified and scheduled an appointment, 13 women failed to show for their 
scheduled appointments, two women were disqualified from participating in the study for 
no longer meeting study criteria (i.e., one woman instigated hormonal birth control within 
the prior month and one woman acknowledged that she had polycystic ovary syndrome). 
Additionally, two women were excluded from data analysis for lack of sexual activity 




4.2.1.1 Group differences in participant characteristics. 
 A series of independent-samples t-tests were conducted to explore Group 
differences in Age, BMI, BDI-II, and overall sexual function (FSFI-Total) (see Table 3). 
Women were between the ages of 20 and 41(M = 26.00, SD = 5.34), and their BMI 
ranged from 18.56 – 30.21 (M = 22.76, SD = 2.97).  Results revealed no significant 
Group differences for Age t(50) = -.33, p = .75, although there was a trend for 
significance for BMI t(51) = -1.95, p = .06, suggesting higher BMI for MDD history 
women.   
 Women’s current BDI-II scores ranged between 0 and 33 (M = 7.29, SD = 8.23), 
indicating an average score in the minimal range for depression (see Figure 2). BDI-II 
scores were statistically different by Group, t(50) = - 4.86, p < .001; specifically, women 
in the control group reported minimal levels of current depression (M = 2.85, SD = 3.56), 
while women in the MDD history group reported levels of current depression that were 
nearing the mild range of depression (M = 12.08, SD = 9.16). A closer look at the BDI-II 
scores for the MDD history group indicated that 2 women met criteria for severe levels of 
depression, 4 women met criteria for moderate levels of depression, and 3 women met 
criteria for mild levels of depression.  The remainder of the women in the MDD history 
group  (N = 16) reported levels of current depression in the minimal range. 
 Women’s FSFI-Total scores ranged between 11 and 36 (M = 29.22, SD = 4.93) 
and FSFI-Total was not statistically different by Group, t(50) = 1.68, p = .10.  Moreover, 
no Group differences were observed for the individual FSFI domains. In general, a wide 




skewed towards higher sexual function (see Figure 2). Inspection of the FSFI-Total 
scores indicated that 8 women in the MDD history group and 5 women in the control 
group met criteria for clinical levels of FSD (FSFI-Total < 26.5).  
 
Table 3. Group differences for the total sample and by group status 
 Total Sample 
N = 53 
MDD History Group 
N = 25 
Control Group 
N = 28 
 
 Mean SD Mean SD Mean SD t (51) 
Age 26.00 (5.34) 26.20 (5.73) 25.71 (5.06) -0.33 
BMI 22.75 (2.96) 23.57 (3.72) 22.02 (1.87) -1.95 
BDI-II   7.29 (8.23) 12.08 (9.16)   2.85 (3.56) -4.86** 
FSFI-Total 29.22 (4.93) 28.00 (5.16) 30.27 (5.16)   1.68 
Note: Note: BMI = body mass index; BDI-II = Beck’s Depression Inventory-II; FSFI-
Total = Female Sexual Function Index total score.  





                    a 
b  
 




4.2.1.2 Demographic characteristics. 
 Forty-six women identified as Caucasian (90%), three identified as African 
American (6 %), one identified as Hispanic (2%), and one identified as Other (2%), a 
racial makeup that is not unusual given the ethnic population of Northern New England. 
The majority of women (92%) reported that they had some college education or a college 
degree and the majority (90%) identified as exclusively or predominantly heterosexual.  
Lastly, the majority of the women were in a committed relationship (87%) and had been 
in the relationship for 1-5 years (74%) (see Table 4). 
 
Table 4. Demographic characteristics for the total sample and by group status  
 
Total Sample 
N = 53 
MDD History Group 
N = 25 
Control Group 
N = 28 
 N % N % N % 
Ethnicity       
Caucasian 48 90 24 96 24 86 
African-American 3   6 0   0 3 10 
Hispanic 1   2 1   4 0   0 
Other 1   2 0   0 1   4 
Education       
College Degree 36 68 14 56 22 78 
Some College 13 24 8 32 5 18 
School Degree 3   6 2   8 1   4 
Some High School 1   2 1   4 0   0 
Sexual Orientation       
Heterosexual 48 90 22 88 26 92 
Bisexual 2 4 1 4 1 4 
Homosexual 3 6 2 8 1 4 
Relationship Status       
Single, dating 7 13 5 20 2 7 
Committed 46 87 20 80 26 93 
Relationship Length       
<1 year 14 26 7 28 7 25 




4.2.2 Hormone Values 
 Cortisol values for the entire sample ranged between 4.14 – 22.08 nmol/L (M = 
8.70, SD = 3.97) and were within the range expected for salivary cortisol (Salimetrics, 
2005). DHEA values ranged between .27 – 1.89 nmol/L (M = .84, SD = .40) and were 
within the range expected for salivary DHEA (Salimetrics, 2010). Values for C/D Ratio 
ranged between 4.27 – 25.61 nmol/L (M = 11.29, SD = 4.94). Significant positive 
correlations were observed for Cortisol and DHEA (r = .49, p < .001), and cortisol and 
C/D Ratio (r = .33, p = .02), while a significant negative correlation was observed for 
DHEA and C/D Ratio (r = -.64, p < .001) (see Table 5). 
 
4.2.2.1 Group differences in hormone values. 
 A series of independent-samples t-tests were conducted to investigate potential 
Group differences in hormone levels (hypothesis 1). Results showed no significant 
relationships between Group and hormones: cortisol t(50) = .26, p = .80, DHEA t(50) = 
.12, p = .95, and C/D Ratio t(50) = .63, p = .53 (see Table 5), indicating that levels of 
cortisol, DHEA, and C/D Ratio did not differ for women based on Group status. As a 
further check to explore the relationship between hormones and depression status, 
Pearson correlations were conducted to investigate the relationship between current levels 
of depression (BDI-II) and hormones. Similar to results for Group, no significant 
relationships were observed for BDI-II and hormones: cortisol (r = .11, p = .45), DHEA 





Table 5. Hormone values for the total sample and by group status 
 Total Sample 
N = 53 
MDD History Group 
N = 25 
Control Group 
N = 28 
 
 Mean SD Mean SD Mean SD t (51) 
Hormones: nmol/L        
Cortisol 8.70 (3.97) 8.55 (3.69) 8.84 (4.27) 0.26 
DHEA .84 (0.40) .85 (0.38) .84 (0.44) 0.12 
C/D Ratio 11.29 (4.94) 10.83 (4.37) 11.70 (5.46) 0.63 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = Cortisol/DHEA Ratio 
 
4.2.3 Correlations between Hormones and Dependent Variables 
4.2.3.1 Correlations between hormones and sexual desire/arousal variables.  
 The first set of correlations conducted for hormones and dependent variables 
examined the relationships between hormones (cortisol, DHEA, C/D Ratio) and sexual 
desire/arousal dependent variables (FSFI-Desire, FSFI-Arousal, FSFQ-Desire, FSFQ-
Arousal) (see table 6). Results revealed no significant correlations between cortisol and 
sexual desire/arousal outcome variables. Correlations for DHEA showed trends for 
significance for FSFI-Desire (r = .25, p = .07), and for FSFQ-Desire (r = .26, p = .07) 
(see figure 3). No significant correlations were observed for C/D Ratio and sexual 
function outcome variables. 
 
4.2.3.2 Correlations between hormones and sexual behavior variables.  
Pearson’s correlations next looked at the relationships between hormones 
(cortisol, DHEA, C/D Ratio) and sexual behavior dependent variables (BISF, HISA) (see 




variables. Results for DHEA observed a significant positive correlation for DHEA and 
BISF (r =. 33, p = .02), suggesting greater frequency of sexual activity during the past six 
months for women with higher DHEA (see figure 4). A significant negative correlation 
was observed for C/D Ratio and BISF (r = -.30, p = .03) (see figure 4), suggesting a 
relationship between a higher C/D Ratio and lower frequency of sexual activity. Lastly, a 
trend for significance was observed for C/D Ratio and HISA (r = -.27, p = .07), 





Table 6. Correlation matrix for hormones and sexual desire/arousal and sexual behavior 
outcome variables 










DHEA  .49**        
C/D Ratio  .33* -.64**       
FSFI-Desire  .11  .25† -.21      
FSFI-Arousal  .10  .10 -.04  .67**     
FSFQ-Desire  .09  .26† -.21  .88**  .68**    
FSFQ-Arousal -.10  .02 -.16  .60**  .83**  .57**   
BISF  .05  .33* -.30*  .68**  .51**  .73**  .30**  
HISA -.24  .06 -.27†  .50**  .39**  .45**  .24  .32* 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = cortisol/DHEA ratio; FSFI-Desire 
= Female Sexual Function Index desire domain; FSFI-Arousal= Female Sexual Function 
Index arousal domain; FSFQ-Desire = Female Sexual Function Questionnaire desire 
domain; FSFQ-Arousal = Female Sexual Function Questionnaire arousal domain; BISF = 
Brief Index of Sexual Functioning, HISA = Hurlbert Index of Sexual Assertiveness.   
†
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Figure 4. Scatterplots of 
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4.2.3.2.1 Correlations between DHEA, C/D Ratio and BISF sub-factors.  
To further explore the significant positive correlation observed between DHEA 
and BISF, and the significant negative correlation observed between C/D Ratio and BISF, 
Pearson’s correlations were conducted for DHEA and the BISF sub-factors, and C/D 
Ratio and the BISF sub-factors to determine if one or more specific sexual activities 
(Kissing, Sexual Fantasy, Solitary Masturbation, Partner Masturbation, Petting, Oral Sex, 
Vaginal Sex, Anal Sex) were underlying the significant correlations (see table 7). Results 
for DHEA and the BISF sub-factors indicated significant positive correlations between 
BISF-Sexual Fantasy (r = .29, p = .04), and BISF-Solitary Masturbation (r =. 48, p < 
.001), showing higher levels of DHEA associated with greater frequency of sexual 
fantasy and masturbation without a partner (see figure 5). The remaining correlations 
between DHEA and BISF sub-factors were not significant. Similarly, Pearson’s, 
correlations conducted for C/D Ratio and the BISF sub-factors indicated significant 
negative correlations for BISF-Sexual Fantasy (r = -.29, p = .04), and BISF-Solitary 
Masturbation (r = -.35, p = .01), suggesting a relationship between a higher C/D Ratio 
and lower frequency of sexual fantasy and solitary masturbation (see figure 6). 
Correlations between C/D Ratio and the remaining sub-factors were not significant. Of 
note, BISF-Partner Masturbation showed nearly a zero correlation with DHEA (r = -.02, 




Table 7. Correlation matrix for DHEA, C/D Ratio and BISF sub-factors 
 















C/D Ratio -.64**         
BISF-Kissing  .04  .02        
BISF-Sexual Fantasy  .29* -.29*  .08       
BISF-S Masturbation  .48** -.35* -.05  .46**      
BISF-P Masturbation -.02 -.00  .38**  .10 -.03     
BISF-Petting  .22 -.26  .51**  .32*  .24  .44**    
BISF-Oral Sex  .14 -.15  .33*  .32*  .27*  .36**  .55**   
BISF-Vaginal Sex  .16 -.18  .50**  .16  .11  .29*  .68**  .66**  
BISF-Anal Sex  .23 -.20  .22  .20  .18  .04  .32*  .25  .31* 
 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = cortisol/DHEA ratio; BISF = Brief 
Index of Sexual Functioning; BISF = Brief Index of Sexual Functioning, BISF-K= BISF-
Kissing; BISF-SF= BISF-Sexual Fantasy; BISF-SM= BISF-Solitary Masturbation; BISF-
PM= BISF-Partner Masturbation; BISF-P= BISF-Petting; BISF-OR= BISF-Oral Sex; 
BISF-VS= BISF-Vaginal Sex 




Figure 5: Scatterplots of the sig
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4.2.3.3 Correlations between hormones and sexual response variables.  
The final set of correlations for hormones and dependent variables examined the 
relationships for hormones (cortisol, DHEA, C/D Ratio) and sexual response variables 
(VPA%, Sub-Max, Pre-SADI: 4 domains, Post-SADI: 4 domains) (see table 8). Results 
showed significant negative correlations between cortisol and Pre-SADI-P (r = -.39, p < 
.01), Pre-SADI-E (r = -.35, p = .01), and Pre-SADI-M (r = -.34, p = .01), pointing to 
associations between higher levels of cortisol and lower physiological, cognitive-
emotional, and motivational aspects of sexual desire and arousal prior to exposure to 
erotic stimuli (see figure 7). The remaining correlations between cortisol and sexual 
response variables were not significant. Results for DHEA and sexual response outcome 
variables indicated no significant correlations. Results for C/D Ratio showed a significant 
negative correlation for Pre-SADI-M (r = -.29, p = .04), while a trend for significance 
was observed for Pre-SADI-E (r = -.25, p = .08). Lastly a significant positive correlation 
was observed for C/D Ratio and VPA% (r = -.29, p = .04), suggesting an association 




 Table 8. Correlation matrix for hormones and sexual response outcome variables 
 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = cortisol/DHEA ratio; VPA% = 
vaginal pulse amplitude; Sub-Max = maximum subjective arousal; Pre-SADI = Sexual 
Arousal and Desire Inventory assessed prior to video; Post-SADI = Sexual Arousal and 
Desire Inventory assessed immediately after video; SADI-P = SADI Physiological, 
SADI-E = SADI Evaluative, SADI-M = SADI Motivational, and SADI-A = SADI 
Aversive. 
*p < .05; **p < .01 
  

















DHEA   .49**            
C/D Ratio   .33* -.64**           
VPA%   .17 -.15 -.29*          
Sub-Max   .05   .05 -.02   .31*         
Pre-SADI-P -.39** -.15 -.21   .11   .09        
Pre-SADI-E -.35* -.08 -.25   .13   .16   .95**       
Pre-SADI-M -.34* -.05  .29*   .06   .18   .90**   .93**      
Pre-SADI-A -.15 -.14 -.03  -.05  -.16   .22   .15   .25     
Post-SADI-P -.18 -.09 -.05   .37**   .62**   .41**   .43**   .43**  -.07    
Post-SADI-E -.16 -.08 -.06   .37**   .65**   .44**   .53**   .51**  -.08   .96**   
Post-SADI-M -.15 -.12 -.00   .33**   .66**   .45**   .51**   .56**   .15   .88**   .92**  
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Figure 8. Scatterplot of the significant correlation between 
 
4.2.4 Correlations between Covariates
4.2.4.1 Correlations between covariates and hormones.
 Pearson’s correlations were 
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Table 9. Correlation matrix for study covariates and hormones 
 Cortisol DHEA C/D Ratio Age BMI 
DHEA     .49**     
C/D Ratio     .33*    -.64**    
Age     .03    -.25     .32*   
BMI     .03    -.12     .14     .26  
Sample-Time    -.03    -.18     .15    -.14    -.24 
Note: DHEA = Dehydroepiandrosterone; C/D Ratio = cortisol/DHEA ratio; BMI = body 
mass index; BDI-II Beck Depression Inventory-II  
*p < .05; **p < .01 
 
4.2.4.2 Correlations between covariates and dependent variables.  
 The last series of Pearson’s correlations explored relationships between potential 
control variables (Age, BDI-II) and dependent variables (sexual desire/arousal, sexual 
behavior, and sexual response), which also allowed for the observation of correlations 
between dependent variables (see table 10). Given the lack of significant associations 
between hormone values and MDD history (i.e., Group status, BDI-II), BDI-II was 
included as a potential covariate for secondary analyses, given the possible negative 
effects of depression on sexual function. Results for Age revealed a significant positive 
correlation for Age and VPA% (r = .28, p = .05), indicating higher VPA% for older 
women. Numerous significant correlations were observed for BDI-II and dependent 
variables: FSFI-Desire (r = -.27, p = .05), FSFI-Arousal (r = -.35, p = .01), FSFQ-
Arousal (r = -.37, p < .01), HISA (r = -.43, p = < .01), Pre-SADI-A  (r = .33, p = .02), 
and Post-SADI-A (r = .30, p = .03). Taken together, these results point to an association 




sexual assertiveness, and higher aversive response to sexual stimuli. 
 Numerous significant correlations were observed between dependent variables. Of 
note, significant positive correlations were observed for VPA% and Sub-Max (r = .36, p 
= .01), Post-SADI-P  (r = .39, p < .01), Post SADI-E (r = .40, p < .01), and Post-SADI- 
M (r = .37 p < .01), indicting concordance between women’s physiological arousal and 
subjective feelings of arousal in the current study sample. Also of interest included 
significant positive correlations for BISF and Pre-SADI-P (r = .28, p = .04), Pre-SADI-E 
(r = .31, p = .03), and Pre-SADI-M (r = -.33, p = .02), pointing to a relationship between 
frequency of sexual activity and anticipatory aspects of sexual desire and arousal to 
sexual stimuli. Lastly, significant negative associations were observed for HISA and Pre-
SADI-A (r = -.42, p < .01), and Post-SADI-A(r = -.38, p = .01), suggesting that higher 
levels of sexual assertiveness are associated with a less aversive anticipation and response 




 Table 10. Correlation matrix for study covariates and dependent variables 
Note: BDI-II Beck Depression Inventory-II; FSFI-D = Female Sexual Function Index-
Desire; FSFI-A= Female Sexual Function Index-Arousal; FSFQ-D = Female Sexual 
Function Questionnaire-Desire; FSFQ-A = Female Sexual Function Questionnaire-
Arousal; BISF = Brief Index of Sexual Functioning, HISA = Hurlbert Index of Sexual 
Assertiveness; VPA% = vaginal pulse amplitude; Sub-Max = maximum subjective 
arousal; Pre-SP = Pre-Sexual Arousal and Desire Inventory (SADI)-Physiological; Pre-
SE = Pre-SADI-Evaluative; Pre-SM = Pre-SADI-Motivational; Pre-SA = Pre-SADI-
Aversive; Post-SP = Post-SADI-Physiological; Post-SE = Post-SADI-Evaluative; Post-
SM = Post-SADI-Motivational; Post-SA = Post-SADI-Aversive. 
*p < .05; **p < .01 
  



























BDI-II -.22                 
FSFI-D -.24 -.27*                
FSFI-A  .07 -.35*  .67**               
FSFQ-D -.20 -.21  .88**   .68**              
FSFQ-A  .12 -.37**  .60**  .83**  .57**             
BISF -.25  -.03  .68**  .51**  .73**  .40**            
HISA  .03 -.43**  .50**  .39**  .45**  .43**  .32*           
VPA%  .28* -.11  .08  .10  .04  .23 -.03  .12          
SubMax -.04   .14   .39**  .43**  .37**  .42**  .33*  .25  .36*         
Pre-SP -.12 -.08  .09  .01  .23  .12  .28*  .21  .08  .09        
Pre-SE -.11 -.17  .20  .12  .30*  .15  .31*  .23  .09  .16  .95**       
Pre-SM -.14 -.13  .17  .10   .31*  .13  .33*  .24  .04  .18  .90**  .93**      
Pre-SA  .04  .33* -.32* -.27* -.24 -.07  .18 -.42** -.11 -.16  .22  .15  .25     
Post-SP  .09 -.18  .34**  .38**  .46**  .39** -.43**  .40**  .39**  .62**  .41**  .43**  .43** -.07     
Post-SE  .04 -.26  .38**  .38**  .47**  .38**  .40**  .41**  .40**  .65**  .44**  .53**  .51** -.08  .96**   
Post-SM  .01 -.12  .32*   .32*  .43**  .32*  .37**  .25  .37**  .66**  .45**  .51**  .56**  .15  .88**  .92**  





4.2.5 Regression Analyses  
4.2.5.1 Hormones and sexual desire/arousal variables. 
4.2.5.1.1 Main effects of DHEA on FSFI-Desire and FSFQ-Desire.  
To further explore the trends for significance observed between DHEA and sexual 
function outcome variables (FSFI-Desire, FSFQ Desire), hierarchical multiple 
regressions were conducted to allow for the control of study covariates (Age, BMI, and 
Sample-Time) to determine if the inclusion of these variables would impact the 
associations between DHEA and measures of sexual desire (see table 11). The regression 
model predicting FSFI-Desire was not significant at Step1 or Step2, ∆F(1, 46) 2.51, p = 
.12, ∆R2 = .05. Similarly, the model predicting FSFQ-Desire was not statistically 





Table 11. Main effects of DHEA on FSFI-Desire and FSFQ-Desire 
Note: DHEA = Dehydroepiandrosterone; FSFI-Desire = Female Sexual Functioning 
Index-Desire domain; FSFQ-Desire = Female Sexual Functioning Questionnaire-Desire 
domain; BMI = body mass index.  
*p < .05; **p < .01 
 
4.2.5.2 Hormones and sexual behavior variables. 
4.2.5.2.1 Main Effects of DHEA and C/D Ratio on BISF. 
Three regression models were conducted to investigate the main effects of DHEA 
on BISF, BISF-Sexual Fantasy, and BISF-Solitary Masturbation while controlling for 
study covariates (Age, BMI, and Sample-Time) (see table 12). The three regression 
models were not significant at Step1. The first model predicting BISF showed a 
statistically significant positive effect for DHEA at Step2 ∆F(1, 47) = 5.71, p = .02, ∆R2 
= .10, indicating  higher levels of DHEA associated with greater frequency of overall 
sexual activity, Β = .34, p = .02. Similarly, the model predicting BISF-Sexual Fantasy 
observed a significant effect for DHEA at Step2, ∆F(1, 47) = 4.26, p = .05, ∆R2 = .08, 
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2        F, ∆F  
1 FSFI-Desire 1 Age -.22 -1.50  .06 .95  
   BMI -.02 -.14     
   Sample-Time .05 .33     
  2 Age -.16 -1.04  .05 2.5  
   BMI .00 .05     
   Sample-Time .11 .71     
   DHEA .23 1.59     
2 FSFQ-Desire 1 Age -.19 -1.23  .04 .70  
   BMI -.05 -.36     
   Sample-Time -.05 -.32     
  2 Age -.14 -.90  .04 2.13  
   BMI -.03 -.18     
   Sample-Time .00 .05     




indicating greater frequency of sexual fantasy for women with higher levels of DHEA, Β 
= .30, p = .05. Lastly, the model predicting BISF-Solitary Masturbation was statistically 
significant at Step2, ∆F (1, 47) = 13.46, p = .001, ∆R2 = .22, indicating greater frequency 
of solitary masturbation for women with higher levels of DHEA, Β = .50, p = .001. 
Next, three regression models were conducted to investigate the effects of C/D 
Ratio on BISF, BISF-Sexual Fantasy, and BISF-Solitary Masturbation, while controlling 
for study covariates (see table 13). The models were not significant at Step1. The first 
model predicting BISF, revealed a significant negative effect for C/D Ratio at Step2, 
∆F(1, 47) = 4.07, p = .05, ∆R2 = .07, suggesting that a higher C/D Ratio is associated 
with a lower frequency of sexual activity, Β = -.30, p =. 05. The model predicting BISF-
Sexual Fantasy was not significant at Step2, ∆F(1, 47) = 3.60, p = .07, ∆R2 = .07, Β = -
.28, p = .07. The third model predicting BISF-Solitary Masturbation showed a 
statistically significant negative effect for C/D Ratio at Step2, ∆F(1, 47) = 6.00, p = .02, 
∆R2 = .11, indicating that a higher C/D Ratio is associated with a lower frequency of 




Table 12. Main effects of DHEA on BISF 
Note: DHEA = Dehydroepiandrosterone; BISF = Brief Index Sexual Functioning; BISF-
SF = Brief Index Sexual Functioning-Frequency of Sexual Fantasy; BISF-SM = Brief 
Index Sexual Functioning-Frequency of Solitary Masturbation; BMI = body mass index. 
*p < .05; **p < .01  
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2 F, ∆F  
1 BISF 1 Age -.22 -.15  .07 1.16  
   BMI .02 .14     
   Sample-Time .12 .86     
  2 Age -.14 -.95  .10 5.71 * 
   BMI .06 .43     
   Sample-Time .21 1.46     
   DHEA .34 2.39 *    
2 BISF-SF 1 Age -.18 -1.28  .08 1.34  
   BMI -.09 -.58     
   Sample-Time .13 .90     
  2 Age -11 -.76  .08 4.26 * 
   BMI -.05 -.35     
   Sample-Time .20 1.41     
   DHEA .30 2.06 *    
3 BISF-SM 1 Age -.12 -.79  .02 .40  
   BMI .04 .29     
   Sample-Time -.11 -.77     
  2 Age .01 .05  .22 13.46 ** 
   BMI .10 .76     
   Sample-Time .01 .07     




Table 13. Main effects of C/D Ratio on BISF 
Note: C/D Ratio = cortisol/DHEA ratio; BISF = Brief Index Sexual Functioning; BISF-
SF = Brief Index Sexual Functioning-Frequency of Sexual Fantasy; BISF-SM = Brief 
Index Sexual Functioning-Frequency of Solitary Masturbation; BMI = body mass index. 
*p < .05; **p < .01  
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2        F, ∆F  
1 BISF 1 Age .12 .86  .07 1.16  
   BMI -.22 -1.52     
   Sample-Time .02 .14     
  2 Age .19 1.33  .07 4.07 * 
   BMI -.13 -.85     
   Sample-Time .06 .38     
   C/D Ratio -.30 -2.12 *    
2 BISF-SF 1 Age -.18 -1.28  .08 1.34  
   BMI .13 .90     
   Sample-Time -.09 -.58     
  2 Age -.10 -.64  .07 3.58  
   BMI .19 1.34     
   Sample-Time -.05 -.37     
   C/D Ratio -.28 -1.89     
3 BISF-SM 1 Age -.12 -.79  .02 .40  
   BMI -.11 -.77     
   Sample-Time .04 .29     
  2 Age -.01 -.12  .11 5.98 * 
   BMI -.22 -.22     
   Sample-Time .59 .59     




4.2.5.2.2 Main effects of Cortisol and C/D Ratio on HISA. 
To further explore the trends for significance shown by the correlation analyses 
for cortisol and HISA, and C/D Ratio and HISA, two regression analyses allowing for the 
control of study covariates were conducted (see table 14). The first model regressing 
HISA on cortisol was not significant at Step1or Step2. The second model regressing 
HISA on C/D Ratio was not significant at Step1. The addition of C/D Ratio at Step2 
provided a significant negative effect, ∆F(1, 40) = 5.30, p = .03, ∆R2 = .11, indicating a 





Table 14. Main effects of Cortisol (model 1) and C/D/Ratio (model 2) on HISA 
Note: C/D Ratio = cortisol/DHEA ratio; HISA = Hurlbert Index of Sexual assertiveness; 
BMI = body mass index. 
*p < .05; **p < .01 
 
4.2.5.3 Hormones and sexual response variables. 
4.2.5.3.1 Main effects of Cortisol and C/D Ratio on SADI. 
Three regression models were conducted to explore the main effects of cortisol on 
Pre-SADI-P, Pre-SADI-E, and Pre-SADI-M while controlling for study covariates (Age, 
BMI, and Sample-Time) (see table 15). The three models were not statistically significant 
at Step1. The model predicting SADI-P observed a statistically significant negative effect 
for cortisol at Step2, ∆F(1, 46) = 8.37, p < .01, ∆R2 = .15, indicating higher levels of 
cortisol for women with lower subjective feelings of physiological sexual desire/arousal 
prior to erotic stimuli, Β = -.39, p < .01. Following in this trend, the second model 
predicting SADI-E also observed a significant negative effect for cortisol at Step2, ∆F(1, 
46) = 6.53, p = .02, ∆R2 = .12, indicating higher levels of cortisol for women with lower 
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2 F, ∆F  
1 HISA 1 Age .09 .54  .05 .78  
   BMI .17 1.05     
   Sample-Time -.13 -.81     
  2 Age .12 .79  .06 2.65  
   BMI .13 .85     
   Sample-Time -.16 -1.01     
   Cortisol -.25 -1.63     
2 HISA 1 Age .09 .54  .05 .78  
   BMI .17 1.05     
   Sample-Time -.13 -.81     
  2 Age .18 1.18  .11 5.30 * 
   BMI .26 1.68     
   Sample-Time -.08 -.53     




subjective cognitions/feelings of sexual desire/arousal prior to erotic stimuli, Β = -.38, p = 
.02. Lastly, the model predicting SADI-M was also significant at Step2, ∆F(1, 46) = 6.26, 
p = .02, ∆R2 = .11, indicating higher levels of cortisol for women with a lower motivation 
to act upon sexual desire/arousal, Β = -.33, p = .02.  
Next, two regression models were conducted to explore the main effects of C/D 
Ratio on Pre-SADI-E, and Pre-SADI-M, while controlling for study covariates (see table 
17). The models were not statistically significant at Step1. In the first model predicting 
Pre-SADI-E, the addition of C/D Ratio at Step2 did not proved a significant effect, 
although a trend for significance was observed, ∆F(1, 46) = 3.60, p = .06, ∆R2 = .07, Β = 
-.28, p = .06. For the model predicting Pre-SADI-M, the addition of C/D Ratio at Step2 





Table 15. Main effects of Cortisol on SADI 
Note: Pre-SADI-P = Sexual Arousal and Desire Inventory-Physiological domain (pre-
video); Pre-SADI-E = Sexual Arousal and Desire Inventory-Evaluative domain (pre-
video); and Pre-SADI-M = Sexual Arousal and Desire Inventory-Motivational domain 
(pre-video); BMI = body mass index. 
*p < .05; **p < .01  
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2        F, ∆F  
1 Pre-SADI-P 1 Age -.15 -.10  .03 .52  
   BMI .10 .68     
   Sample-Time .08 .54     
  2 Age -.15 -1.10  .15 8.37 ** 
   BMI .09 .66     
   Sample-Time .09 .65     
   Cortisol -.39 -2.89 **    
2 Pre-SADI-E 1 Age -.15 -.98  .04 .62  
   BMI .12 .80     
   Sample-Time .12 .81     
  2 Age -.15 -1.05  .12 6.53 * 
   BMI .11 .79     
   Sample-Time .13 .91     
   Cortisol -.35 -2.56 *    
3 Pre-SADI-M 1 Age -.17 -.17  .05 .85  
   BMI .13 .93     
   Sample-Time .13 .84     
  2 Age -.16 -1.17  .11 6.26 * 
   BMI .13 .91     
   Sample-Time .13 .93     




Table 16. Main effects of C/D Ratio on SADI 
Note: C/D Ratio =cortisol/DHEA ratio; Pre-SADI-E = Sexual Arousal and Desire 
Inventory-Evaluative domain (pre-video); and Pre-SADI-M = Sexual Arousal and Desire 
Inventory-Motivational domain (pre-video); BMI = body mass index. 
*p < .05; **p < .01 
 
4.2.5.3.2  Main effect of C/D Ratio on VPA%. 
 The final regression model explored the main effects of C/D Ratio on VPA% 
while allowing for control of study covariates (see table 18). Although a significant effect 
was not observed for Step1, inspection of the beta coefficients showed a significant 
positive effect for Age, Β = .33, p = .02. At Step2 the addition of C/D Ratio did not 
provide an additive significant effect, ∆F(1, 46) = 2.82, p = .10, ∆R2 = .05, Β = .25, p = 
.10.  
  
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2        F, ∆F  
1 Pre-SADI-E 1 Age -.15 -.98  .04 .62  
   BMI .12 .80     
   Sample-Time .12 .81     
  2 Age -.07 -.45  .07 3.60  
   BMI .18 1.25     
   Sample-Time .16 1.05     
   C/D Ratio -.28 -1.90     
2 Pre-SADI-M 1 Age -.17 -1.17  .05 .85  
   BMI .13 .93     
   Sample-Time .13 .84     
  2 Age -.07 -.46  .09 4.72 * 
   BMI .21 1.44     
   Sample-Time .16 1.12     




Table 17. Main effects of C/D Ratio on VPA% 
Note: C/D Ratio =cortisol/DHEA ratio; VPA% = percent increase in vaginal pulse 
amplitude; BMI = body mass index. 
*p < .05; **p < .01 
 
4.2.6 Moderation Analyses 
4.2.6.1 Interaction effects of hormones and Group on sexual function. 
A series of hierarchical regression analyses was conducted to test the potential 
moderating effects of hormones and Group on the sexual function dependent variables 
identified as statistically significant in the regression analyses. However, none of the 
models showed a statistically significant increase in R2 with the addition of the 
interaction terms at Step3. 
 Specifically, relevant to sexual behavior variables, the model testing the 
interaction of DHEA and Group on BISF, did not reveal a significant additive effect for 
the interaction term at Step3, ∆F(1, 45) = .01, p = .91, ∆R2 = .00. Similarly, significant 
effects were not observed for models testing the interaction effects of DHEA and Group 
on BISF-Sexual Fantasy, ∆F(1, 45) = .24, p = .63, ∆R2 = .00, or BISF-Solitary 
Masturbation, ∆F(1, 45) = 1.2, p = .28, ∆R2 = .02. Likewise, no significant effects were 
shown for models testing the interaction of C/D Ratio and Group on BISF, ∆F(1, 45) = 
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2 F, ∆F  
1 VPA% 1 Age .33 2.33  .12 2.04  
   BMI -.07 -.49     
   Sample-Time -.07 -.49     
  2 Age .25 1.71  .05 2.85  
   BMI -.13 -.89     
   Sample-Time -.10 -.69     




.88, p = .35, ∆R2 = .02, or BISF-Solitary Masturbation, ∆F(1, 45) = .05, p = .83, ∆R2 = 
.00. Lastly, an additive effect was not shown for the interaction of C/D Ratio and Group 
on HISA, ∆F(1, 45) = .14, p = .71, ∆R2 = .00. 
Relevant to sexual response variables, models testing the interaction of cortisol 
and Group on the Pre-SADI domains, did not reveal significant effects at Step3 for the 
interaction term on Pre-SADI-P, ∆F(1, 45) = 1.67, p = .20, ∆R2 = .03, Pre-SADI-E, ∆F(1, 
45) = .62, p = .44, ∆R2 = .01, or Pre-SADI-M, ∆F(1, 45) = 2.61, p = .11, ∆R2 = .05. 
Similarly, significant effects were not observed for models testing the interaction effects 
of C/D Ratio and Group on Pre-SADI-P, ∆F(1, 45) = .61, p = .44, ∆R2 = .01, or Pre-
SADI-M, ∆F(1, 45) = .98, p = .33, ∆R2 = .02. 
As a further check, regression analyses were conducted to test the moderation of 
hormones (cortisol, DHEA and C/D Ratio) and current depression (BDI-II) on the sexual 
function outcome measures. Similar to results for Group, no significant interaction effects 
were observed.  
 
4.2.7 Secondary Analyses 
4.2.7.1 Regression analyses.  
Given the negative correlations observed for BDI-II and FSFI-Desire (r = -.27) 
and FSFQ-Desire (r = -.21), I decided to conduct additional unplanned regression 
analyses to determine if the addition of the covariate BDI-II would impact the 
significance of the relationship between DHEA and measures of sexual desire. In 




depression (Basson et al., 2010), due to the potential negative effects of depression on 
sexual function, the control of current depression symptomology was deemed plausible to 
inform further research in the area of hormones and female sexuality.  
Two regression models were conducted; the first regressed FSFI-Desire on DHEA 
and the second regressed FSFQ-Desire on DHEA. In both models the covariates (Age, 
BMI, Sample-Time, and BDI-II) were entered at Step1, followed by the addition of 
DHEA at Step2. The model predicting FSFI-Desire was not significant at Step1, ∆F(4, 
46) = 2.60, p = .06, ∆R2 = .17, although inspection of the beta coefficients showed 
significant negative contributions provided by Age, Β = -.33, p = .03, and BDI-II, Β = -
.35, p = .02. The addition of DHEA at Step2 provided an additive significant effect, 
∆F(1, 45) = 4.90, p = .03, ∆R2 = .08, showing higher levels of DHEA associated with 
greater sexual desire, Β = .31, p = .03. The model predicting FSFQ-Desire was not 
statistically significant at Step1 or Step2, although Step2 maintained the trend for 
significance observed for the correlation analyses, ∆F(1, 44) 3.20, p = .08, ∆R2 = .06, , Β 





Table 18. Main effects of DHEA on FSFI-Desire and FSFQ-Desire controlling for BDI-II 
Note: DHEA = Dehydroepiandrosterone; FSFI-Desire = Female Sexual Functioning 
Index-Desire domain; FSFQ-Desire = Female Sexual Functioning Questionnaire-Desire 
domain; BMI = body mass index; BDI-II = Beck’s Depression Inventory-II. 
*p < .05; **p < .01 
  
Model Dependent  Variable Step Predictor β t-Value  R
2
, ∆R2        F, ∆F  
1 FSFI-Desire 1 Age -.33 -2.28 * .17 2.42  
   BMI .01 .08     
   Sample-Time .00 .03     
   BDI-II -.35 -2.48 *    
  2 Age -.26 -1.85  .08 4.90 * 
   BMI .05 .38     
   Sample-Time .08 .56     
   BDI-II -.37 -2.78 **    
   DHEA .31 2.21 *    
2 FSFQ-Desire 1 Age -.28 -1.84  .12 1.53  
   BMI -.03 -.19     
   Sample-Time -.09 -.61     
   BDI-II -.29 -1.97     
  2 Age -.22 -1.48  .06 3.17  
   BMI .01 .05     
   Sample-Time -.03 -.17     
   BDI-II -.31 -2.17 *    




4.2.7.2 Mediation analyses. 
To further explore the significant relationships between DHEA and FSFI-Desire, 
and DHEA and BISF, while controlling for BDI-II, a series of unplanned mediation 
analyses was conducted to investigate the potential meditating effect of FSFI-Desire on 
the relationships between DHEA and BISF, BISF-Sexual Fantasy, and BISF-Solitary 
Masturbation (see figure 9). Specifically, Preacher and Hayes’ SPSS macros (Preacher & 
Hayes, 2008) were utilized to estimate the total and specific indirect effects of DHEA on 
the outcome variables (BISF, BISF-Sexual Fantasy, BISF-Solitary Masturbation) through 
the mediator FSFI-Desire, while controlling for the potential influence of covariates 
(Age, BMI, Sample-Time, BDI-II). The Preacher and Hayes’ SPSS macros generate 
bootstrap confidence intervals that allow for an increase in power for studies with small 
sample sizes. 
The overall model fit for BISF was significant [F(6, 44) = 8.73; p < .001; R2 = 
0.54 (95% confidence intervals ranged from 9.98 to 16.65)]. Including the mediator 
FSFI-Desire in the model reduced the relationship between DHEA and BISF from 
significant, t(51) = 2.38, p = .03, to non-significant, t(51) = 1.14, p = .26, suggesting the 
mediation of DHEA and BISF by FSFI-Desire. Similarly, the model fit for BISF-Sexual 
Fantasy was significant [F(6, 44) = 3.80; p < .001; R2 = 0.34 (95% confidence intervals 
ranged from .18 to 3.86)]. The inclusion of the mediator in the model reduced the 
relationship between DHEA and BISF-Fantasy from significant, t(51) = 2.25, p = .03, to 
non-significant, t(51) = 1.35, p = .18, pointing to the mediation of DHEA and BISF-




significant [F(6, 44) = 4.38; p < .001; R2 = 0.38 (95% confidence intervals ranged from 
.01 to 2.80)]. The inclusion of the mediator significantly reduced the relationship between 
DHEA and BISF-Masturbation, t(51) = 3.21, p <.01, suggesting the mediation of DHEA 
and BISF-Masturbation by FSFI-Desire. Unlike previous models, the relationship 
between DHEA and BISF-Masturbation remained statistically significant, t(51) = 2.58, p 
= .01. Overall, these results are consistent with models indicating the mediation of DHEA 
and frequency of sexual activity by sexual desire, but should be interpreted with caution 





      
      

































Figure 9. Coefficients for the mediation of FSFI-Desire on the relationship 
between a: DHEA and BISF, b: DHEA and BISF-Sexual Fantasy, and c: DHEA 
and BISF-Solitary Masturbation. Numbers in parenthesis correspond to 
coefficients for the total effect. FSFI-Desire = Female Sexual Function Index-
Desire; BISF = Brief Index of Sexual Function 















    


























5.1 Main Study 
The main aim of the current study was to investigate the relationship between the 
C/D Ratio and lower sexual function in women with and without a history of depression 
to determine if the C/D Ratio would provide a common biological mechanism to explain 
the high comorbidity (Cyranowski, Bromberger, et al., 2004) between MDD and FSD. 
Although numerous studies have observed associations between a high cortisol/DHEA(S) 
ratio and MDD (Goodyer et al., 2003; Michael et al., 2000), no study to date has directly 
investigated the relationship between the cortisol/DHEA ratio and sexual function. A 
number of studies have associated high levels of DHEA(S) with positive sexual function 
(Basson et al., 2010; S. Davis et al., 2005; Turna et al., 2005), suggesting that the ratio 
between cortisol and DHEA may be implicated in sexual function. Indeed, there are 
numerous pathways in which the high cortisol/DHEA(S) ratio observed in MDD may 
exert direct/indirect effects on sexual function (Basson et al., 2010). 
 Contrary to my first hypothesis, this study failed to reveal a significant relationship 
between the C/D Ratio and MDD history in premenopausal women with and without low 
sexual function. Similarly, this study failed to support the third study hypothesis that the 
relationship between the C/D Ratio and lower sexual function would be greater for 
women with a history of MDD. However, relevant to my second hypothesis, numerous 
associations were observed for hormones and measures of sexual function. In particular, 
results showed for the first time a relationship between a high C/D Ratio and lower 




prior to exposure to erotic stimuli. Analyses conducted to explore the individual effects of 
cortisol and DHEA with the effects of the C/D Ratio revealed a pattern of effects that 
appears specific to each hormone. In particular, higher DHEA was associated with 
greater frequency of sexual activity, particularly sexual fantasy and solitary masturbation. 
On the other hand, cortisol was associated with lower anticipatory aspects of sexual 
desire and arousal (physiological, cognitive-emotional, and motivational) prior to 
exposure to erotic stimuli. Lastly, secondary analyses, controlling for levels of current 
depression, showed DHEA positively associated with women’s sexual desire. Moreover, 
results suggested that sexual desire mediated the relationship between DHEA and 
frequency of sexual activity. 
 
5.1.1 C/D Ratio and MDD History 
My first hypothesis proposed that the C/D Ratio would predict MDD history; 
specifically, that women in the MDD history group would have a higher C/D Ratio when 
compared to women in the control group. This hypothesis was based on studies 
associating cortisol hypersecretion with both current and past MDD (Plotsky et al., 1998; 
E Young et al., 2000), a high cortisol/DHEA ratio with MDD (Goodyer et al., 2003), and 
the premise that, in the context of anabolic balance (Maninger et al., 2009), the ratio 
between cortisol and DHEA may provide a more accurate assessment of MDD history, 
given that DHEA(S) has been shown to antagonize the negative effects of cortisol in the 




hormones (cortisol and DHEA) were also investigated to enable comparison with the 
effects of the C/D Ratio.  
 Despite the wealth of literature supporting the association between cortisol and the 
onset and maintenance of depression (Goodyer et al., 2000; Plotsky et al., 1998; 
Vreeburg et al., 2009), this study did not observe a significant relationship between 
cortisol and a history of MDD. Although there are many potential explanations relevant 
to the current study that might explain the lack of significant results (as discussed below), 
it is possible, as the authors of a recent meta-analysis concluded, that there is not “firm 
evidence” for a difference of salivary cortisol between MDD and controls (Knorr et al., 
2010; Knorr, Vinberg, Kessing, & Wetterslev, 2011).  
 Similar to cortisol, the current study did not observe a significant association 
between DHEA and MDD history. This result is less surprising, given the less-
established relationship between DHEA(S) and MDD, and the limited and inconsistent 
findings from past studies investigating DHEA(S) in MDD (Markianos et al., 2007; 
Morrison et al., 2011). Moreover, evidence suggesting that DHEA(S) levels rise during 
the early phase of depression, but decline with MDD persistence, highlights the 
complexity of assessing DHEA(S) levels in MDD (Goodyer et al., 2003). 
 Furthermore, the current study did not support my first hypothesis that women with 
a history of MDD would have a significantly higher C/D Ratio than control women. 
Although scholars have hypothesized that the cortisol/DHEA(S) ratio may provide a 
more accurate representation of HPA axis function in MDD than cortisol alone 




the present study did not support that conjecture. Indeed, prior studies investigating the 
cortisol/DHEA(S) ratio in MDD have reported varied results. In particular, studies have 
observed a high cortisol/DHEA(S) ratio in MDD in the absence of high levels of cortisol 
(H. Young et al., 2002) and in the presence of high levels of cortisol (Goodyer et al., 
2001), while other studies have not observed an association between the 
cortisol/DHEA(S) ratio and MDD (Takebayashi et al., 1998). 
 It is plausible that factors specific to the current study may account for the null 
relationship observed between hormones and MDD history. Specifically, due to 
recruitment difficulties, only 3 women in the MDD history group met criteria for current 
MDD; the remaining 22 women met criteria for past MDD. Although evidence suggests 
that the cortisol awakening response (CAR) precedes and predicts the onset of MDD 
(Harris et al., 2000), and that individuals with remitted MDD have significantly elevated 
waking cortisol (Bhagwagar et al., 2003), it is feasible that the lack of current depression 
in the MDD history group may have contributed to the observed lack of difference 
between groups in the present study. Indeed, results from a recent, longitudinal study  (N 
= 4467) suggested that high salivary cortisol does not predict the onset of MDD, but did 
indicate that low mean salivary cortisol and a small difference between morning and 
evening cortisol concentrations may be risk factors for MDD (Grynderup et al., 2013). It 
is also possible that high levels of cortisol in MDD may distinguish a subset of MDD that 
was not assessed in the current study; in particular, evidence suggests that high cortisol is 
specific to melancholic vs. atypical MDD (Gold & Chrousos, 2002).  




salivary collection. Although basal cortisol concentrations have been shown to 
distinguish MDD from controls, it is plausible that assessment of the CAR in the current 
study may have provided a more reliable methodology for differentiating cortisol levels 
between women with a history of MDD and controls. Nonetheless, conflicting results 
have been shown for CAR in MDD; although some studies report an increased CAR 
(Bhagwagar et al., 2005), others report a blunted CAR in MDD (Fries, Dettenborn, & 
Kirschbaum, 2009; Huber, Issa, Schik, & Wolf, 2006). Lastly, related to salivary 
collection, it is possible that some participants may have collected samples at times other 
than instructed and/or may not have adhered to study requirements (e.g., restriction of 
alcohol/drugs), thus impacting hormone concentrations. Although a strong effort was 
made to control the timing of morning salivary sampling across the three days of 
collection, including instructing participants to text the PI immediately after collection; it 
is impossible to verify if samples were collected upon waking in the morning as 
instructed.  
 
5.1.2 C/D Ratio and Sexual Function  
 The second study hypothesis proposed that a higher C/D Ratio would be 
associated with lower sexual function. This hypothesis was based on evidence associating 
lower concentrations of DHEA(S) with lower sexual function (Basson et al., 2010; S. 
Davis et al., 2005) and the premise that, in the context of anabolic balance (Maninger et 
al., 2009), the ratio between cortisol and DHEA(S) may provide a more accurate 




& Meston, 2010). The individual effects of cortisol and DHEA were also investigated to 
enable comparison with the effects of the C/D Ratio. Numerous sexual function outcome 
variables were utilized, including questionnaires, behavioral self-reports, and 
physiological assessments, given our lack of knowledge regarding the influence of these 
hormones on varying aspects of female sexual desire and arousal. 
 
5.1.2.1 Sexual desire/arousal.  
Initial correlation analyses showed trends of significance for DHEA and self-
report measures of desire (FSFI-Desire, FSFQ-Desire); however, controlling for study 
covariates (Age, BMI, Sample-Time) did not increase the significance of these 
associations. Moreover, no associations were observed for DHEA and measures assessing 
sexual arousal (FSFI-Arousal, FSFQ-Arousal). It is feasible that the lack of significant 
associations between DHEA and sexual desire/arousal in the current study may be 
explained by the operationalization of sexual dysfunction. Although women reported a 
wide range of sexual function, women with higher sexual function were better 
represented in the study sample. Indeed, only one-quarter of the women (N = 13) met 
criteria for FSD in the domain of sexual desire as assessed by the FSFI. It is plausible that 
a greater representation of women with FSD would have increased the likelihood of 
observing significant associations between DHEA and sexual desire/arousal.  
 
5.1.2.2 Sexual behavior.  




sexual activity as assessed by the BISF, as well as the BISF sexual fantasy and solitary 
masturbation items. To my knowledge, this is the first time DHEA has been associated in 
the literature with frequency of female sexual activity. Adding evidence to the observed 
relationship between DHEA and sexual activity, a recent study showed that early 
postmenopausal women treated with 10 mg DHEA daily for one year experienced a 
significant increase in number of episodes of sexual intercourse, along with a significant 
improvement in overall sexual function (Genazzani et al., 2011). Animal models also 
provide evidence regarding the effects of DHEA on sexual behavior; in particular, 
treatment with DHEA significantly increased proceptive behaviors (i.e., the female's 
sexual motivation to approach a male and to show solicitatious behaviors) in rats as early 
as one week after starting treatment, suggesting central effects of DHEA on sexual 
behavior (Pluchino et al., 2013). 
A previous study showed solitary sexual desire, but not dyadic sexual desire, 
positively liked with testosterone (van Anders, 2012). In a similar fashion, results from 
the current study indicated that the BISF items significantly associated with DHEA were 
sexual fantasy and solitary masturbation, but not partnered masturbation (r = -.02), or 
other partnered sexual activities. Moreover, the association of DHEA with frequency of 
solitary masturbation is in agreement with prior studies linking testosterone to 
masturbation frequency, but not with sexuality involving the partner (Bancroft, Sanders, 
Davidson, & Warner, 1983; Myers, Dixen, Morrissette, Carmichael, & Davidson, 1990). 
Previous studies have also associated testosterone replacement therapy in pre and 




including sexual fantasy and masturbation (Nathorst-Böös, Flöter, Jarkander-Rolff, 
Carlström, & Schoultz, 2006; Shifren et al., 2000). Taking the current results in 
conjunction with the previous literature, it possible that DHEA may be exerting effects on 
sexual behavior through the synthesis of DHEA into sex steroids, including testosterone 
(Labrie, 2001).  
Moreover, DHEA was associated with the frequency of engaging in sexual 
behaviors (i.e. solitary masturbation, sexual fantasy) that may reflect the “pure desire” for 
pleasure versus the frequency of engaging in sexual behaviors such as kissing, 
intercourse, and oral sex, in which “pure desire” may be complicated by psychosocial 
motivations (van Anders, 2012). Indeed, the literature suggests that partnered sexual 
activity often occurs in the absence of sexual desire (Meston & Buss, 2007). It has been 
suggested that masturbation in particular may be a useful indicator of the desire for 
sexual pleasure since solitary masturbation is removed from the complexity of partnered 
sexuality (Bancroft & Graham, 2011). Although the current study did not distinguish 
between sexual fantasy in a solitary vs. dyadic context, the argument can be made that 
women engage in sexual fantasy motivated by the desire for sexual pleasure, given 
evidence indicating that women utilize sexual fantasy to increase sexual arousal during 
masturbation and intercourse (Lunde, Larsen, Fog, & Garde, 1991). The current results 
showing DHEA associated with frequency of solitary masturbation and sexual fantasy 
offer support for the proposition that acknowledging psychosocial differences between 
solitary and partnered sexual activity may allow for a greater understanding of potential 





Relevant to the C/D Ratio and sexual behavior, results showed the C/D Ratio 
negatively and significantly associated with BISF overall frequency of sexual activity and 
BISF solitary masturbation. This result was observed in the absence of an association 
between cortisol and BISF, offering support for concept of anabolic balance, since the 
ratio of cortisol to DHEA, not absolute cortisol levels, predicted lower frequency of 
sexual activity. It is plausible that high levels of cortisol in the context of low DHEA (i.e., 
high C/D Ratio) may exert inhibitory effects on sexual behavior, particularly 
masturbation, potentially due to the effect of stress. 
A significant negative association was also observed for the C/D Ratio and sexual 
assertiveness as assessed by the HISA in the absence of associations with cortisol or 
DHEA. Sexual assertiveness (i.e., the ability to communicate sexual desires and needs to 
one’s partner), has been associated with greater frequency of sexual activity, orgasm 
frequency, subjective sexual desire, and sexual satisfaction (Hurlbert, 1991), emphasizing 
the potential negative impact of low sexual assertiveness on women’s sexual function. 
Although testosterone has been associated with assertive characteristics (Grant & France, 
2001), a recent study failed to observe an association between higher testosterone and 
sexual assertiveness assessed by the HISA (van Anders & Dunn, 2009). On the other 
hand, results from unpublished data suggest that higher testosterone may promote 
cognitive self-views associated with directness and a lack of behavioral inhibition 
regarding sexual activity (Dundon, Toufexis, & Rellini, in preparation). Given potential 




suggest that levels of cortisol, and more specifically, the ratio between hormones, may 
play an important role in determining the impact of the androgens on a woman’s 
motivation to be sexually assertive.  
 
5.1.2.3 Sexual response.  
Cortisol was negatively and significantly associated with women’s Pre-SADI 
assessment of cognitive emotional (Pre-SADI-E), physiological (Pre-SADI-P), and 
motivational (Pre-SADI-M) aspects of sexual/desire and arousal in anticipation of the 
erotic stimuli presentation, but not with Post-SADI assessment following the presentation 
of erotic stimuli. The cognitive-emotional domain of the SADI assesses the subjective 
awareness of sexual arousal, while the physiological domain assesses the physiological 
changes that accompany becoming sexually aroused, and the motivation domain assesses 
the drive to act upon the desire to engage in sexual behavior (Toledano & Pfaus, 2006). 
Results also showed the C/D Ratio negatively and significantly associated with Pre-
SADI-M; however, it is probable that cortisol was driving this significance, given that a 
greater effect size was observed for cortisol when compared to C/D Ratio. 
The literature provides little guidance regarding the impact of baseline levels of 
cortisol on female sexuality; however, taken together, these results suggest that higher 
cortisol and a higher C/D Ratio, potentially associated with low mood and/or stress, may 
have a negative impact on women’s anticipatory assessment of sexual desire and arousal 
prior to sexual stimuli. It has been hypothesized that cortisol hyperactivity may increase 




women’s subjective assessment of sexual stimuli. Interestingly, the post-video SADI 
domains were not associated with cortisol or the C/D Ratio. These results raise the 
possibility that focusing on the sexual stimuli presented in the video increased women’s 
physiological arousal that in turn, had a positive impact on their subjective feelings of 
post-video desire and arousal through a decrease in anxiety and negative cognitions 
(Hamilton, Rellini, & Meston, 2008). Indeed, in the current study, women’s physiological 
(VPA%) and subjective (Sub-Max) sexual arousal were significantly and positively 
correlated post-video, and post-video SADI-E, SADI-P, and SADI-M were significantly 
correlated with VPA% and Sub-Max.  
Initial correlational analyses indicated that the C/D Ratio was positively and 
significantly correlated with VPA%; however including the covariates in a regression 
analysis reduced the association between VPA% and the C/D Ratio to non-significance, 
influenced by the positive and significant correlation between age and VPA%. The initial 
association between C/D Ratio and VPA% was unexpected given evidence indicating 
that VPA% is an indicator of female sexual arousal (Laan, Everaerd, Van Berlo, & Rijs, 
1995), the assumption that a high cortisol/DHEA(S) ratio may have a negative impact on 
female sexuality (Hamilton & Meston, 2013), and results from a single study indicating a 
negative association between VPA% and the cortisol/DHEA-S ratio assessed post erotic 
video presentation (Hamilton & Meston, 2010). The same study did not observe an 





5.1.2.4 Assessment of sexual function. 
Although the current study utilized numerous measures to assess women’s sexual 
desire and arousal (e.g., self-report questionnaires, behavioral self-reports and 
physiological assessment), behavioral assessments including frequency of sexual activity 
and sexual assertiveness were the outcome measures that showed the greatest 
associations with the C/D Ratio and with DHEA. It has recently been proposed that 
sexual behaviors are understudied despite the "face validity and empirical support" for 
their inclusion in studies of women's sexuality (van Anders, 2012). Indeed, it is possible 
that sexual behavior might be conceptualized as the manifestation of women's sexual 
desire. Moreover, the assessment of women’s behavioral expressions of sexual 
desire/arousal may provide information that unlike self-report questionnaires is unfiltered 
by their beliefs and expectations regarding their sexuality and unimpeded by their 
construal of questions assessing sexual function. In particular, questionnaires are often 
hampered by the social desirability bias, in which frequency of symptoms are under-
reported to present oneself in an acceptable light. These results offer support for the more 
frequent inclusion of behavioral assessments in studies seeking to elucidate the role of 
hormones in women’s sexuality. 
 
5.1.3 Moderation of C/D Ratio and Sexual Function by MDD History 
The third study hypothesis proposed that the relationship between the C/D Ratio 
and sexual function would be moderated by MDD group status, so that the relationship 




a history of MDD. Although the current study observed relationships between the C/D 
Ratio and lower sexual function, particularly in the domains of sexual behavior and the 
anticipatory evaluation of sexual stimuli, the relationships did not differ depending upon 
Group status (MDD history vs. Controls). Furthermore, observed associations for DHEA 
and sexual function, and cortisol and sexual function did not differ relative to Group. As 
discussed above, it is plausible that the operationalization of MDD in the current study to 
include women with a history of MDD may have obscured potential interacting effects of 
Group and hormones on sexual function. Alternatively, it is possible that a high 
cortisol/DHEA ratio may be relevant for only a subset of women with MDD (i.e., those 
with melancholic depression). 
It is also feasible that the comorbidity between MDD and FSD is not linked to a 
high cortisol/DHEA ratio. Although the current study did not observe an association 
between Group and sexual function, greater feelings of current depression as assessed by 
the BDI-II were negatively and significantly associated with sexual function in the 
domains of FSFI-Desire, FSFI-Arousal, FSFQ-Arousal, and HISA. These results concur 
with previous data indicating that symptoms of depression often co-occur with lower 
sexual function (Fabre & Smith, 2012). Since the present study observed lower sexual 
function but not hormones associated with current depression, it is plausible that sexual 
difficulties in women with MDD may be a consequence of MDD and/or may reflect 





5.1.4 Secondary Analyses 
Given significant correlations between BDI-II and measures of sexual desire, and 
evidence linking depression with lower sexual desire (Fabre & Smith, 2012), secondary 
analyses were conducted to explore the relationship between DHEA and sexual desire, 
while controlling for current depressive symptomology. Consistent with prior studies 
(Basson et al., 2010; S. Davis et al., 2005), analyses revealed DHEA significantly 
associated with sexual desire (i.e., FSFI-Desire; significance trend for FSFQ-desire), 
when controlling for levels of current depression. Moreover, the relationships between 
DHEA and overall frequency of sexual behaviors, sexual fantasy, and solitary 
masturbation were explained by women’s sexual desire, suggesting that DHEA may exert 
its effects on sexual behavior through its effects on desire. However, since the 
directionality of the observed relationships cannot be established, these results should be 
interpreted with caution. 
While sexual desire was significantly and negatively associated with current 
depression symptomology (BDI-II), frequency of sexual behavior as assessed by the 
BISF was not associated with BDI-II, suggesting that frequency of sexual activity 
including masturbation and sexual fantasy may be unaffected by lowered mood. This 
association is interesting in light of a prior study in which women with depression 
reported a greater interest in masturbation than control women (Frohlich & Meston, 
2002). It is plausible, as these authors suggested, that women with lowered mood may 




but may refrain from engaging in sexual activities with a partner due to rumination about 
evaluation and/or rejection.  
Moreover, although secondary analyses revealed a positive association between 
DHEA and desire, DHEA was not associated with Group or current depression (BDI-II), 
suggesting the possibility that DHEA may not act via a nonandrogen pathway (e.g., F-
aminobutyric acid and/or N-methyl-D-aspartate receptors), as has been suggested 
previously (Basson et al., 2010), to improve mood and in turn women’s sexual function. 
Instead, it is possible that the potential effect of DHEA on sexual desire may be unrelated 
to the potential positive effect of DHEA on mood, with the limitation that women with a 
history of MDD in the current study were experiencing current levels depression that 
were only approaching the mild range of depression as assessed by the BDI-II (M = 
12.08). 
 
5.1.5 Limitations and Future Directions 
As discussed in depth above, a key limitation of this study was the 
operationalization of both MDD and FSD. It is possible that the small number of women 
with current MDD (N= 3) in the MDD history group may have accounted for the lack of 
relationship between the C/D Ratio and MDD history group. Similarly, it is feasible that 
the small number of women who met criteria for FSD (N = 13) may have made it difficult 
to detect potential significant associations between hormones and measures of sexual 




between the C/D Ratio, depression, and sexual function in women who meet criteria for 
clinical levels of MDD and FSD.   
Another study limitation was the operationalization of sexual activity frequency 
with the BISF. Specifically, the dimension of the BISF utilized in the current study was 
an 8-item scale that assessed the frequency of each type of sexual behavior with one 
response for each type of behavior. The Frequency dimension of the BISF-W has 
revealed statistically significant differences between women with impaired sexual 
function and healthy women (Mazer et al., 2000). However, in the future, researchers 
may wish to extend the current results by utilizing a more comprehensive measure of 
sexual behavior frequency to enable a more thorough investigation of the sexual activities 
that were related to hormones in the current study (i.e., overall frequency of sexual 
behaviors, frequency of masturbation and frequency of sexual fantasy). Moreover, 
although all of the participants in the present study had a current sexual partner and had 
engaged in sexual activity during the past four weeks, it is possible that relationship 
factors may have impacted women’s frequency of sexual activity. 
Similar to other studies investigating salivary hormones (Basson et al., 2010), the 
present study observed marked variability in concentrations of salivary cortisol and 
DHEA; in particular, the standard deviation for both hormones were nearly half as large 
as the group means. Although post-hoc power analyses indicated that there was sufficient 
power (.78) to detect medium effect sizes for many of the variables tested, it is possible 
that a larger sample size would have enabled the detection of statistically significant 




association was not observed for C/D Ratio and self-report measures of sexual 
desire/arousal, the effect sizes for C/D ratio and sexual desire were nearing those for 
DHEA and sexual desire, suggesting the possibility that a significant effect may have 
been observed in a larger sample of women. 
Lastly, since this is a cross sectional study, the directionality of the observed 
relationships cannot be established. For example, frequency of sexual activity has been 
shown to influence hormone levels, specifically testosterone (van Anders, Hamilton, 
Schmidt, & Watson, 2007). Relevant to the current study, it is plausible that frequency of 
sexual activity and feelings of sexual desire may influence levels of DHEA. Moreover, it 
is also feasible that frequency of sexual activity and levels of sexual assertiveness may 
impact cortisol concentrations. In the future, researchers may wish to utilize longitudinal 




 Results from the current study did not support the hypothesis that the relationship 
between the C/D Ratio and sexual function would be greater for women with a history of 
MDD than for women without a history of MDD.  Moreover, no associations were 
observed for MDD history and cortisol, DHEA, and/or the C/D Ratio. It is feasible that 
factors specific to the current study, including the operationalization of MDD and FSD, 
may have contributed to a lack of significant results. However, it is also plausible that the 





 This study offered support for the hypothesis that the C/D Ratio would predict 
lower sexual function, specifically in the behavioral domains of frequency of sexual 
activity and sexual assertiveness. Furthermore, this is the first time DHEA has been 
associated in the literature with frequency of sexual activity. In addition, secondary 
analyses, controlling for current depressive symptomology, concurred with previous data 
linking DHEA with sexual function in the domain of sexual desire and suggested that the 
relationship between DHEA and frequency of sexual activity was mediated by desire. 
Results also showed cortisol associated with the predisposition to have a negative 
assessment of sexual desire and arousal prior to erotic stimuli.  
 Taken together, these results suggest that the effects of the C/D Ratio on female 
sexual function are not associated with a comorbid history of MDD. However, relevant to 
female sexual function, results suggest that a high C/D Ratio may have inhibitory effects 
on sexual assertiveness and frequency of sexual activity, while high cortisol may 
negatively impact women's anticipation of sexual stimuli. On the other hand, high DHEA 
may have facilitatory effects on frequency of sexual activity through heightened sexual 
desire. These results contribute to a further understanding of the roles of cortisol, DHEA 
and the C/D Ratio in female sexuality and offer support for future studies investigating 
the role of these adrenal hormones in female sexual function, including the treatment of 
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Appendix A: List of Abbreviations 
ACTH Adrenocorticotropic hormone 
BDI-II Beck's Depression Inventory-II 
BISF Brief Index of Sexual Functioning 
BISF-SF Brief Index of Sexual Functioning-Sexual Fantasy 
BISF-SM Brief Index of Sexual Functioning-Solitary Masturbation 
BMI Body mass index 
CAR Cortisol awakening response 
C/D Ratio Ratio between cortisol and dehydroepiandrosterone 
CRH Corticotropin releasing hormone 
DHEA Dehydroepiandrosterone 
DHEA-S Dehydroepiandrosterone sulfate 
DHEA(S) Joint reference: dehydroepiandrosterone, dehydroepiandrosterone sulfate 
FSD Female sexual dysfunction 
FSFI Female Sexual Function Index 
FSFQ Female Sexual Function Questionnaire 
HISA Hurlburt Index of Sexual Assertiveness 
HPA Axis Hypothalamic pituitary adrenal axis 
HPG Axis Hypothalamic pituitary gonadal axis 
HSDD Hypoactive sexual desire disorder 
MDD Major depressive disorder 
Pre-SADI Sexual Arousal and Desire Inventory: assessed pre erotic video 
Post-SADI Sexual Arousal and Desire Inventory: assessed post erotic video 
SADI Sexual Arousal and Desire Inventory 
SADI-P Sexual Arousal and Desire Inventory-Physiological 




SADI-M Sexual Arousal and Desire Inventory-Motivational 
SADI-A Sexual Arousal and Desire Inventory-Aversive 
SCID-I Structured Clinical Interview for the DSM-IV-TR 
Sub-Max Subjective maximum arousal during erotic video 





Appendix B: Demographics Questionnaire 
 
What is your age? ______________________ 
 
Please indicate your highest level of education: 
   
_____ Some High School or less 
_____ High School graduate/GED 
_____ Some College 
_____ 2-year degree 
_____ 4-year degree 
_____ Advanced degree (Ph.D., M.S., J.D., etc.) 
 
Please indicate your race/ethnicity (indicate all that apply): 
 
_____ Caucasian/White 
_____ African American/Black 
_____ Native American 
_____ Hispanic 
_____ Asian 
_____ Other; please explain__________________________________________ 
 
Please indicate your relationship status: 
 
_____ Single, Dating 
_____ Single, Not Dating 
_____ In a Committed Relationship 
_____ Married/Common Law/Civil Union 
 
Please indicate the length of your relationship with your current partner: 
 
_____ 0-6 months 
_____ 6-12 months 
_____ 1-2 years 
_____ 3-5 years 
_____ 5-10 years 
_____ Greater than 10 years 
At what age did you start your menstrual cycle (your period)? __________ 
 










Please indicate your sexual orientation: 
 
_____ Exclusively heterosexual 
_____ Predominantly heterosexual, only incidentally homosexual 
_____ Predominantly heterosexual, but more than incidentally homosexual 
_____ Equally heterosexual and homosexual 
_____ Predominantly homosexual but more than incidentally heterosexual 
_____ Predominantly homosexual but only incidentally heterosexual 
_____ Exclusively homosexual 
 
 
Please indicate your height: ____________________  
 






Appendix C: Female Sexual Function Index (FSFI) 
INSTRUCTIONS: These questions ask about your sexual feelings and responses during the past 4 
weeks. Please answer the following questions as honestly and clearly as possible. In answering 
these questions the following definitions apply: 
 
Sexual activity includes intercourse, caressing, foreplay, and masturbation. 
Sexual intercourse is defined as penile penetration (entry) of the vagina. 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
 
CIRCLE ONLY ONE CHOICE PER QUESTION: 
 
Sexual desire or interest is a feeling that included wanting to have a sexual experience, feeling 
receptive to a partner’s sexual initiation, and thinking or fantasizing about having sex. 
 
 
1. Over the past 4 weeks, how often did you  
feel sexual desire or interest? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
  
2. Over the past 4 weeks, how would you rate 
your level (degree) of sexual desire or 
interest? 
5 = Very high 
4 = High  
3 = Moderate 
2 = Low 
1 = Very low or none at all 
  
3. Over the past 4 weeks, how often did you  
feel sexually aroused ("turned on") during  
sexual activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
 
  
4. Over the past 4 weeks, how would you rate  
your level of sexual arousal ("turn on")  
during sexual activity or intercourse? 
 
5 = Very high 
4 = High  
3 = Moderate 
2 = Low 
1 = Very low or none at all 






5. Over the past 4 weeks, how confident were 
you about becoming sexually aroused during 
sexual activity or intercourse? 
 
5 = Very high confidence 
4 = High confidence 
3 = Moderate confidence 
2 = Low confidence 
1 = Very low or no confidence 




6. Over the past 4 weeks, how often have you 
been satisfied with your arousal 
(excitement) during sexual activity or 
intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
 
  
7. Over the past 4 weeks, how often did you 
become sexually aroused (lubricated or 
"wet") during sexual activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never  
N/A= No sexual activity 
 
  
8. Over the past 4 weeks, how difficult was it 
to become aroused (lubricated or “wet”) 
during sexual activity or intercourse? 
 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
N/A= No sexual activity 
 
  
9. Over the past 4 weeks, how often did you 
maintain your arousal (lubrication or 
"wetness”) until completion of sexual 
activity or intercourse? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 






10. Over the past 4 weeks, how difficult was it 
to maintain your arousal (lubrication or 
"wetness”) until completion of sexual 
activity or intercourse? 
 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
N/A= No sexual activity 
 
  
11. Over the past 4 weeks, when you had sexual 
stimulation or intercourse, how often did 
you reach orgasm (climax)? 
 
5 = Almost always or always 
4 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
2 = A few times (less than half the time) 
1 = Almost never or never 
N/A= No sexual activity 
 
  
12. Over the past 4 weeks, when you had sexual 
stimulation or intercourse, how difficult was 
it for you to reach orgasm (climax)? 
1 = Extremely difficult or impossible 
2 = Very difficult 
3 = Difficult 
4 = Slightly difficult 
5 = Not difficult 
N/A= No sexual activity 
 
  
13. Over the past 4 weeks, how satisfied were 
you with your ability to reach orgasm 
(climax) during sexual activity or 
intercourse? 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
N/A= No sexual activity 
 
  
14. Over the past 4 weeks, how satisfied have 
you been with the amount of emotional 
closeness during sexual activity between you 
and your partner? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 






15. Over the past 4 weeks, how satisfied have 
you been with your sexual relationship with 
your partner? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
 
  
16. Over the past 4 weeks, how satisfied have 
you been with your overall sexual life? 
 
5 = Very satisfied 
4 = Moderately satisfied 
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied 
1 = Very dissatisfied 
  
17. Over the past 4 weeks, how often did you 
experience discomfort or pain during vaginal 
penetration? 
 
1 = Almost always or always 
2 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
4 = A few times (less than half the time) 
5 = Almost never or never 
N/A= No vaginal penetration 
 
  
18. Over the past 4 weeks, how often did you 
experience discomfort or pain following 
vaginal penetration? 
 
1 = Almost always or always 
2 = Most times (more than half the time) 
3 = Sometimes (about half the time) 
4 = A few times (less than half the time) 
5 = Almost never or never 
N/A= No vaginal penetration 
 
  
19. Over the past 4 weeks, how would you rate 
your level (degree) of discomfort or pain 
during or following vaginal penetration? 
 
1 = Very high 
2 = High  
3 = Moderate 
4 = Low 
5 = Very low or none at all 












Appendix D: Female Sexual Function Questionnaire (FSFQ)                                                                            
 
These questions ask about your sexual activity over the last 4 weeks. Please answer every 
question by marking one box with a cross. If you are unsure about how to answer, please give 
the best answer you can. In answering these questions the following definition of “sexual 
activity” applies: Sexual Activity—includes any activity which may result in sexual stimulation or 
sexual pleasure, e.g., intercourse, caressing, foreplay, masturbation (i.e., self-masturbation or 
your partner masturbating you), and oral sex (i.e., your partner giving you oral sex). 
 
 
1.    Over the last 4 weeks, how often have 
you had pleasurable thoughts and feelings 
about sexual activity? 
 
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often 
 
2.    Over the last 4 weeks, how often have 
you wanted to be sensually touched and 
caressed by your partner?     
   
   1.  [ ] Not at all        
   2.  [ ] Rarely     
   3.  [ ] Sometimes    
   4.  [ ] Often     
   5.  [ ] Very often  
 
 
3.    Over the last 4 weeks, how often have 
you wanted to take part in sexual activity?  
    
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often  
4.    Over the last 4 weeks, how often have 
you initiated sexual activity with your partner?  
     
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
   4.   [ ] Often     
    5.  [ ] Very often  
 
 
5.    Over the last 4 weeks, how often have 
you been sensually touched and caressed by 
your partner?   
    
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often  
 
6.    Over the last 4 weeks, in general, how 
 enjoyable has it been to be sensually touched 
and caressed by your partner? 
 
    0.  [ ] I have not been touched or caressed 
    1.  [ ] Not enjoyable       
    2.  [ ] Slightly enjoyable   
    3.  [ ] Moderately enjoyable   
    4.  [ ] Very enjoyable    







7.     Over the last 4 weeks, how often did you 
have a feeling of “warmth” in your vagina/ 
genital area when you took part in sexual 
activity? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all       
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often 
  
8.     Over the last 4 weeks, in general, how 
much “warmth” did you feel in your vagina/ 
genital area when you took part in sexual 
activity?    
  
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] None        
    2.  [ ] Slightly “warm”    
    3.  [ ] Moderately “warm”   
    4.  [ ] Very “warm”    
    5.  [ ] Extremely “warm” 
 
 
9.     Over the last 4 weeks, how often did you 
have a sensation of “pulsating” (“tingling”) in 
your vagina/genital area when you took part in 
sexual activity? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often 
 
10.     Over the last 4 weeks, in general, how 
much “pulsating” (“tingling”) in your     
vagina/genital area did you notice when you 
took part in sexual activity? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] No sensation        
    2.  [ ] A mild sensation   
    3.  [ ] A moderate sensation   
    4.  [ ] A strong sensation   
    5.  [ ] A very strong sensation 
 
 
11.     Over the last 4 weeks, how often did 
you notice vaginal wetness/lubrication when 
you took part in sexual activity? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often 
 
12.     Over the last 4 weeks, in general, how 
much vaginal wetness/lubrication did you 
notice when you took part in sexual activity? 
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] No wetness/lubrication   
     2.  [ ] Slightly wet/lubricated   
     3.  [ ] Moderately wet/lubricated  
     4.  [ ] Very wet/lubricated   




13.      Over the last 4 weeks, how often did 
you have feelings of emotional sexual arousal 
(e.g., feeling excited, feeling “turned on,” 
wanting sexual activity to continue) when you 
took part in sexual activity? 
 
14.     Over the last 4 weeks, how much 
emotional sexual arousal (e.g., feeling excited, 
feeling “turned on,” wanting sexual activity to    






0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often 
0.  [ ] I did not take part in sexual activity 
     1.  [ ] None 
     2.  [ ] Slightly aroused       
     3.  [ ] Moderately aroused   
     4.  [ ] Very aroused    
     5.  [ ] Extremely aroused  
   
 
15.     Over the last 4 weeks, how often did 
you take part in sexual activity with 
penetration (e.g., vaginal penetration and 
intercourse)?  
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] Once/twice    
     2.  [ ] 3 – 4 times   
     3.  [ ] 5 – 8 times    
     4.  [ ] 9 – 12 times 
     5.  [ ]13 – 16 times 
     6.  [ ] >16 times 
 
16.     Over the last 4 weeks, in general, how 
much did you enjoy penetration and 
intercourse? 
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] Not enjoyable  
     2.  [ ] Slightly enjoyable    
     3.  [ ] Moderately enjoyable   
     4.  [ ] Very enjoyable    
     5.  [ ] Extremely enjoyable. 
 
17.     Over the last 4 weeks, how often did 
you experience pain in your vagina/genital 
area during or after sexual activity (e.g., 
penetration, intercourse)? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Very often      
    2.  [ ] Often    
    3.  [ ] Sometimes    
    4.  [ ] Rarely    
    5.  [ ] Not at all  
18.     Over the last 4 weeks, in general, how 
much pain did you experience in your vagina/ 
genital area during or after sexual activity 
(e.g., penetration, intercourse)? 
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] Extremely painful       
     2.  [ ] Very painful    
     3.  [ ] Moderately painful   
     4.  [ ] Slightly painful    
     5.  [ ] No Pain 
 
19.     Over the last 4 weeks, how often did 
you take part in sexual activity without 
penetration (e.g., masturbation, oral sex)? 
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] Once/twice    
     2.  [ ] 3 – 4 times    
     3.  [ ] 5 – 8 times    
     4.  [ ] 9 – 12 times 
     5.  [ ]13 – 16 times 
     6.  [ ] >16 times 
 
20.     Over the last 4 weeks, in general, how 
much did you enjoy sexual activity without 
penetration (e.g., masturbation, oral sex)? 
 
     0.  [ ] I did not take part in sexual activity 
     1.  [ ] Not enjoyable  
     2.  [ ] Slightly enjoyable    
     3.  [ ] Moderately enjoyable   
     4.  [ ] Very enjoyable    




21.     Over the last 4 weeks, how often did 
you feel emotionally close to your partner 
when you took part in sexual activity? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Sometimes    
    3.  [ ] Often     
    4.  [ ] Very often    
    5.  [ ] Every time 
22.     Over the last 4 weeks, how often have 
you been worried or anxious about pain during 
sexual activity? 
   
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Every time        
    2.  [ ] Very often    
    3.  [ ] Often     
    4.  [ ] Sometimes    
    5.  [ ] Not at all  
 
23.     Over the last 4 weeks, did you feel good 
about yourself when you were sexually active? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Slightly    
    3.  [ ] Moderately    
    4.  [ ] Very     
    5.  [ ] Extremely 
24.     Over the last 4 weeks, how often did 
you have an orgasm when you took part in 
sexual activity (may be with or without a 
partner)?   
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Sometimes    
    3.  [ ] Often     
    4.  [ ] Very often    
    5.  [ ] Every time 
25.     Over the last 4 weeks, in general, how  
pleasurable were the orgasms that you had? 
 
     0.  [ ] I did not have any orgasms 
     1.  [ ] Not pleasurable    
     2.  [ ] Slightly pleasurable    
     3.  [ ] Moderately pleasurable  
     4.  [ ] Very pleasurable   
     5.  [ ] Extremely pleasurable 
 
26.     Over the last 4 weeks, in general, how 
easy was it for you to reach orgasm? 
 
     0.  [ ] I did not have any orgasms 
     1.  [ ] Very difficult        
     2.  [ ] Quite difficult     
     3.  [ ] Neither easy nor difficult  
     4.  [ ] Quite easy    
     5.  [ ] Very easy  
27.    Over the last 4 weeks, how confident 
have you felt about yourself as a sexual 
partner? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Not at all        
    2.  [ ] Slightly    
    3.  [ ] Moderately    
    4.  [ ] Very     






In answering the following questions the following definition of “sexual life” applies: Sexual 
life—both the physical sexual activities and the emotional sexual relationship that you have with 
your partner. 
 
28.     Thinking about your sexual life over the 
last 4 weeks, how often did you look forward 
to sexual activity? 
    1.  [ ] Not at all        
    2.  [ ] Rarely     
    3.  [ ] Sometimes    
    4.  [ ] Often     
    5.  [ ] Very often    
      
29.   Thinking about your sexual life over the 
last 4 weeks, did you feel disappointed with 
your sexual response (e.g., ability to become 
aroused, lubrication)? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Extremely        
    2.  [ ] Very    
    3.  [ ] Moderately    
    4.  [ ] Slightly     
    5.  [ ] Not at all 
30.   Thinking about the last 4 weeks, how 
much did you worry that your partner may 
look for another sexual relationship because of 
problems with your sexual life? 
 
    0.  [ ] I did not take part in sexual activity 
    1.  [ ] Extremely        
    2.  [ ] Very    
    3.  [ ] Moderately    
    4.  [ ] Slightly     
    5.  [ ] Not at all 
31.   Thinking about the last 4 weeks, how 
much did you worry about your partner’s 
negative feelings about your sexual life (e.g., 
partner feeling angry, hurt, rejected)? 
 
    1.  [ ] Extremely        
    2.  [ ] Very    
    3.  [ ] Moderately    
    4.  [ ] Slightly     
    5.  [ ] Not at all  
 
32.    Thinking about your sexual life over the 
last 4 weeks, how did you feel about the 
frequency of your sexual activity? 
 
     1.  [ ] A lot less than you desired  
     2.  [ ] A little less than you desired  
     3.  [ ] About right for you   
     4.  [ ] A little more than you desired  
     5.  [ ] A lot more than you desired 
 
33.    In general, how important is being able to 
have an enjoyable sexual life to you?    
   
    1.  [ ] Not at all        
    2.  [ ] Slightly    
    3.  [ ] Moderately    
    4.  [ ] Very     
    5.  [ ] Extremely 
34.    Over the last 4 weeks, taking the whole 
of your sexual life into account, how satisfied 
have you been?      
 
     1.  [ ] Not satisfied        
     2.  [ ] Slightly satisfied   
     3.  [ ] Moderately satisfied   
     4.  [ ] Very satisfied    





Appendix E: Question from the Brief Index of Sexual Functioning (BISF) 
Using the scale to the right, indicate how frequently you have engaged in the following 
experiences during the past month? (An answer is required for each, even if it may not apply 
to you.) 
   
Kissing  (0) Not at all 
Sexual fantasy  (1) Once 
Masturbation alone  (2) 2 or 3 times  
Mutual masturbation  (3) Once a week 
Petting and foreplay  (4) 2 or 3 times per week 
Oral sex  (5) Once a day 
Vaginal penetration or intercourse  (6) More than once a day 





Appendix F: Hurlbert Index of Sexual Assertiveness (HISA) 
                                                                             
This inventory is designed to measure the degree of sexual assertiveness you have in the sexual 
relationship with your partner. This is not a test, so there are no right or wrong answers. Please 
answer every question by marking one box with a cross. If you are unsure about how to answer, 





1.    I feel uncomfortable talking during sex. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
2.    I feel that I am shy when it comes to sex. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
3.    I approach my partner for sex when I 
desire it. 
 
    0.  [ ] All of the time       
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
4.    I think I am open with my partner about 
my sexual needs. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
5.    I enjoy sharing my sexual fantasies with 
my partner. 
 
    0.  [ ] All of the time      
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
6.    I feel uncomfortable talking to my friends 
about sex. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
7.     I communicate my sexual desires to my 
partner. 
 
    0.  [ ] All of the time     
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never 
 
8.     It is difficult for me to touch myself during 
sex.     
   
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    





9.     It is hard for me to say no even when I do 
not want sex. 
      
    0.  [ ] All of the time       
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
10.     I am reluctant to describe myself as a 
sexual person.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
11.     I feel uncomfortable telling my partner 
what feels good.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
12.     I speak up for my sexual feelings. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
13.      I am reluctant to insist that my partner 
satisfy me.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
14.     I find myself having sex when I do not 
really want it.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never    
 
15.     When a technique does not feel good, I 
tell my partner.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
16.     I feel comfortable giving sexual praise to 
my partner. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never 
 
17.     It is easy for me to discuss sex with my 
partner.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
18.     I feel comfortable in initiating sex with 
my partner. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    





19.     I find myself doing sexual things that I do 
not like. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
20.     Pleasing my partner is more important 
than my pleasure. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
21.     I feel comfortable telling my partner how 
to touch me. 
 
    0.  [ ] All of the time     
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
22.     I enjoy masturbating myself to orgasm. 
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
23.     If something feels good, I insist on doing 
it again.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never 
 
24.     It is hard for me to be honest about my 
sexual feelings.  
 
    0.  [ ] All of the time        
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    
    4.  [ ] Never  
 
25.     I try to avoid discussing the subject of 
sex. 
 
    0.  [ ] All of the time 
    1.  [ ] Most of the time   
    2.  [ ] Some of the time   
    3.  [ ] Rarely    







Appendix G: Sexual Arousal and Desire Inventory  (Pre and Post-SADI) 
 (Pre-Video instructions) 
 
Sexual arousal is defined as the physiological responses that accompany or follow sexual desire. 
For example, when you feel sexually aroused, your heart might beat faster or your palms may 
get sweaty, and you may feel a moistness of the vagina. Sexual desire is an energizing force that 
motivates a person to seek out or initiate sexual contact and behavior. You can think of it as a 
hunger or a sexual “drive” that leads you to seek out sexual contact. 
 
On the other side of this page is a list of words that might describe your present feelings of 
desire and arousal. There is no “right” or “wrong” answer. Please indicate to what extent each 
word describes how you feel, by circling the number that describes the feeling most accurately.  
 
 
 (Post-Video instructions) 
 
On the other side of this page is a list of words that might describe how you felt while viewing 
the video clip. There is no “right” or “wrong” answer. Please indicate to what extent each word 
describes how you felt while watching the video clip you were exposed to. Please use the 







0   1   2   3   4   5   Anticipatory          0   1   2   3   4   5    Frustrated        
0   1   2   3   4   5   Tingly all over        0   1   2   3   4   5    Lustful      
0   1   2   3   4   5   Restrained         0   1   2   3   4   5    Entranced      
0   1   2   3   4   5   Anxious         0   1   2   3   4   5    Aversion      
0   1   2   3   4   5   Driven         0   1   2   3   4   5    Hot      
0   1   2   3   4   5   Frigid         0   1   2   3   4   5    Tempted      
0   1   2   3   4   5   Sensitive to touch        0   1   2   3   4   5    Passionate      
0   1   2   3   4   5   Sluggish            0   1   2   3   4   5    Fantasize about sex       
0   1   2   3   4   5   Urge to satisfy/be satisfied          0   1   2   3   4   5    Repressed      
0   1   2   3   4   5   Enthusiastic          0   1   2   3   4   5    Disturbed      
0   1   2   3   4   5   Unhappy         0   1   2   3   4   5    Flushed      
0   1   2   3   4   5   Wet        0   1   2   3   4   5    Impatient      
0   1   2   3   4   5   Horny         0   1   2   3   4   5    Sensual       
0   1   2   3   4   5   Resistant         0   1   2   3   4   5    Breathe faster/pant      
0   1   2   3   4   5   Warm all over        0   1   2   3   4   5    Displeasure      
0   1   2   3   4   5   Excited         0   1   2   3   4   5    Stimulated      
0   1   2   3   4   5   Tingling in genital area       0   1   2   3   4   5    Tingling in gut      
0   1   2   3   4   5    Uninterested       0   1   2   3   4   5     Forget everything  
0   1   2   3   4   5    Pleasure          0   1   2   3   4   5    Repulsion      
0   1   2   3   4   5    Heart beats faster        0   1   2   3   4   5    Sexy      
0   1   2   3   4   5    Happy         0   1   2   3   4   5    Quivering sensations      
0   1   2   3   4   5    Angry        0   1   2   3   4   5    Insensible      
0   1   2   3   4   5    Attractive         0   1   2   3   4   5    Seductive      
0   1   2   3   4   5    Powerful         0   1   2   3   4   5    Genitals reddish      
0   1   2   3   4   5    Naughty         0   1   2   3   4   5    Unattractive      
0   1   2   3   4   5    Alluring         0   1   2   3   4   5    Good      





Appendix H: Beck’s Depression Inventory-II (BDI-II) 
                                                                             
 
After reading each group of statements carefully, please check the number (0, 1, 2, 3) and 
statement in each group which best describes the way you have been feeling the past four 
weeks, including today.  If several statements within a group seem to apply equally well, place a 




1.  _____ (0) I do not feel sad today. 
     _____ (1) I do not feel sad. 
     _____ (2) I am sad all the time and I can’t     
                       snap out of it 
     _____ (3) I am so sad or unhappy that I   
                      can’t stand it. 
 
2.  _____ (0) I am not particularly discouraged  
                       about the future. 
     _____ (1) I feel discouraged about the  
                       future. 
     _____ (2) I feel I have nothing to look  
                       forward to. 
     _____ (3) I feel the future is hopeless and  
                       that things cannot improve. 
 
3.  _____ (0) I do not feel like a failure. 
     _____ (1) I feel I have failed more than the  
                       average person. 
     _____ (2) As I look back on my life, all I can  
                      see is a lot of failures. 
     _____ (3) I feel I am a complete failure as a  
                      person. 
 
4.  _____ (0) I get as much satisfaction out of  
                       things as I used to. 
     _____ (1) I don’t enjoy things the way I used  
                       to. 
     _____ (2) I don’t get any real satisfaction  
                       out of anything anymore. 
     _____ (3) I am dissatisfied or bored with  
                       everything. 
 
5.  _____ (0) I don’t feel particularly guilty. 
     _____ (1) I feel guilty a good part of the  
                      time. 
     _____ (2) I feel quite guilty most of the  
                      time. 
     _____ (3) I feel guilty all the time. 
 
6.  _____ (0) I don’t feel I am being punished. 
     _____ (1) I feel I may be punished. 
     _____ (2) I expect to be punished. 
     _____ (3) I feel I am being punished.  
 
 
7.  _____ (0) I don’t feel disappointed in   
                       myself. 
     _____ (1) I am disappointed in myself. 
     _____ (2) I am disgusted with myself. 
     _____ (3) I hate myself. 
 
8.  _____ (0) I don’t feel I am any worse than  
                       anybody else. 
     _____ (1) I am critical of myself for my  
                       weaknesses or mistakes. 
     _____ (2) I blame myself all the time for my  
                       faults. 
     _____ (3) I blame myself for everything bad  






9.  _____ (0) I don’t have any thoughts of     
                       killing myself. 
     _____ (1) I have thoughts of killing myself,   
                       but I would not carry them out. 
     _____ (2) I would like to kill myself. 
     _____ (3) I would kill myself if I had the  
                      chance.    
 
10.  _____ (0) I don’t cry anymore than usual.  
       _____ (1) I cry more now than I used to. 
       _____ (2) I cry all the time now. 
       _____ (3) I used to be able to cry, but now                 
                         I can’t cry even though I want to.
   
 
11.  _____ (0) I am no more irritated now than  
                         I ever am.  
       _____ (1) I am slightly more irritated now  
                         than usual.  
       _____ (2) I am quite annoyed or irritated a     
                         good deal of the time. 
       _____ (3) I feel irritated all the time. 
 
12.  _____ (0) I have not lost interest in other  
                        people.  
       _____ (1) I am less interested in other  
                        people than I used to be. 
       _____ (2) I have lost most of my interest in  
                        other people. 
       _____ (3) I have lost all of my interest in  
                         other people. 
 
 
13.  _____ (0) I make decisions about as well  
                         as I ever could.  
       _____ (1) I put off making decisions more  
                         than I used to. 
       _____ (2) I have greater difficulty in  
                         making decisions than before. 
       _____ (3) I can’t make decisions at all  
                         anymore. 
 
14.  _____ (0) I don’t feel I look any worse than  
                          I used to.  
       _____ (1) I am worried that I am looking  
                         old or unattractive. 
       _____ (2) I feel that there are permanent  
                         changes in my appearance that                         
                         make me look unattractive. 
       _____ (3) I believe that I look ugly.  
 
 
15.  _____ (0) I can work about as well as  
                         before. 
       _____ (1) It takes an extra effort to get  
                         started at doing something. 
       _____ (2) I have to push myself very hard  
                         to do anything. 
       _____ (3) I can’t do any work at all. 
 
16.  _____ (0) I can sleep as well as usual. 
       _____ (1) I don’t sleep as well as I used to. 
       _____ (2) I wake up 1-2 hours earlier than  
                         usual and find it hard to get back  
                         to sleep. 
       _____ (3) I wake up several hours earlier  
                         than I used to and cannot get       
                         back to sleep. 
 
17.  _____ (0) I don’t get more tired than  
                         usual. 
       _____ (1) I get tired more easily than I  
                         used to. 
       _____ (2) I get tired from doing almost  
                        anything. 
       _____ (3) I am too tired to do anything 
 
18.  _____ (0) My appetite is no worse than  
                         usual. 
       _____ (1) My appetite is not as good as it  
                         used to be. 
       _____ (2) My appetite is much worse now. 
       _____ (3) I have no appetite at all  





19.  _____ (0) I haven’t lost much weight, if  
                         any, lately. 
       _____ (1) I have lost more than 5 pounds. 
       _____ (2) I have lost more than 10 pounds. 
       _____ (3) I have lost more than 15 pounds. 
 
20.  _____ (0) I am no more worried about my  
                          health than usual. 
       _____ (1) I am worried about physical  
                         problems such as aches and  
                         pains; or upset stomach; or      
                         constipation. 
       _____ (2) I am very worried about physical  
                         problems and it’s hard to think    
                         of much else. 
       _____ (3) I am so worried about my  
                         physical problems that I cannot          
                         think about anything else. 
 
21.  _____ (0) I have not noticed any recent  
                         change in my interest in sex. 
       _____ (1) I am less interested in sex than I  
                         used to be. 
       _____ (2) I am much less interested in sex  
                         now. 
       _____ (3) I have lost interest in sex  
                         completely 
 
 
 
 
  
 
